

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S10 1	97950	gusperimus adh hydrochloride	USPAT	OR	OFF	2006/05/17 13:37
S10 2	11	gusperimus adj hydrochloride	USPAT	OR	OFF	2006/05/17 13:38
S10 3	11	gusperimus and vasculitis	USPAT	OR	OFF	2006/05/17 13:56
S10 4	198	514/551.ccls.	USPAT	OR	OFF	2006/05/17 13:58
S10 5	2	S104 and (deoxyspergualin or gusperimus)	USPAT	OR	OFF	2006/05/17 14:24
S10 6	299	(15-deoxyspergualin or gusperimus)	USPAT	OR	OFF	2006/05/17 13:57
S10 7	755	514/419.ccls.	USPAT	OR	OFF	2006/05/17 14:09
S10 8	1	S107 and S106	USPAT	OR	OFF	2006/05/17 13:58
S10 9	1	S107 and deoxyspergualin	USPAT	OR	OFF	2006/05/17 13:58
S11 0	349	514/634.ccls.	USPAT	OR	OFF	2006/05/17 14:10
S11 1	2	S110 and deoxyspergualin	USPAT	OR	OFF	2006/05/17 13:59
S11 2	1	S110 and spergualin	USPAT	OR	OFF	2006/05/17 14:02
S11 3	493	(deoxyspergualin or spergualin)	USPAT	OR	OFF	2006/05/17 14:10
S11 4	110	514/614.ccls.	USPAT	OR	OFF	2006/05/17 14:13
S11 5	0	S114 and spergualin	USPAT	OR	OFF	2006/05/17 14:09
S11 6	107	514/540.ccls.	USPAT	OR	OFF	2006/05/17 14:10
S11 7	3	S116 and S113	USPAT	OR	OFF	2006/05/17 14:10
S11 8	571	514/616.ccls.	USPAT	OR	OFF	2006/05/17 15:29
S11 9	6	S118 and spergualin	USPAT	OR	OFF	2006/05/17 14:13
S12 0	0	S104 and (spergualin or gusperimus)	USPAT	OR	OFF	2006/05/17 14:24
S12 1	367	514/114.ccls.	USPAT	OR	OFF	2006/05/17 15:30

## EAST Search History

S12 2	709	514/114.ccls.	US-PGPUB; USPAT	OR	OFF	2006/05/17 15:30
S12 3	31	S122 and sphingosine	US-PGPUB; USPAT	OR	OFF	2006/05/17 15:31
S12 4	19	S123 and lung	US-PGPUB; USPAT	OR	OFF	2006/05/17 15:32
S12 5	4	S123 and (fibrosis or fibrotic)	US-PGPUB; USPAT	OR	OFF	2006/05/18 08:39
S12 6	1	"5645839".pn.	US-PGPUB; USPAT	OR	OFF	2006/05/18 08:40
S12 7	1	"6544968".pn.	US-PGPUB; USPAT	OR	OFF	2006/05/18 08:40
S12 8	1	"5266583".pn.	US-PGPUB; USPAT	OR	OFF	2006/05/18 08:41
S12 9	1	"4650484".pn.	US-PGPUB; USPAT	OR	OFF	2006/05/18 12:18
S13 0	0	neuralgia adj differ	US-PGPUB; USPAT	OR	OFF	2006/05/18 12:18
S13 1	0	neuralgia adj differ2	US-PGPUB; USPAT	OR	OFF	2006/05/18 12:18
S13 2	0	neuralgia adj differs	US-PGPUB; USPAT	OR	OFF	2006/05/18 12:18
S13 3	0	neuralgia adj2 differ	US-PGPUB; USPAT	OR	OFF	2006/05/18 12:19
S13 4	0	neuralgia adj different	US-PGPUB; USPAT	OR	OFF	2006/05/18 12:19
S13 5	0	neuralgia adj2 different	US-PGPUB; USPAT	OR	OFF	2006/05/18 12:19
S13 6	0	neuralgias adj2 different	US-PGPUB; USPAT	OR	OFF	2006/05/18 12:19
S13 7	0	neuralgia adj3 different	US-PGPUB; USPAT	OR	OFF	2006/05/18 12:19
S13 8	529	neuralgias	US-PGPUB; USPAT	OR	OFF	2006/05/18 12:19
S13 9	81	S138 and differs	US-PGPUB; USPAT	OR	OFF	2006/05/18 15:27
S14 0	8003	less adj often	US-PGPUB; USPAT	OR	OFF	2006/05/18 15:27
S14 1	51	administered adj3 less adj often	US-PGPUB; USPAT	OR	OFF	2006/05/18 18:34
S14 2	281	dorzolamide	US-PGPUB; USPAT	OR	OFF	2006/05/18 18:34
S14 3	222	S142 and timolol	US-PGPUB; USPAT	OR	OFF	2006/05/18 18:35

## EAST Search History

S14 4	10	S143 and (single adj composition)	US-PGPUB; USPAT	OR	OFF	2006/05/18 18:35
S14 5	5069	(single adj composition)	US-PGPUB; USPAT	OR	OFF	2006/05/18 18:45
S14 6	461	(single adj composition) and ophthalmic	US-PGPUB; USPAT	OR	OFF	2006/05/18 18:36
S14 7	135	(single adj composition) and ophthalmic	USPAT	OR	OFF	2006/05/18 18:38
S14 8	105	S147 and (separately or sequential or subsequently)	USPAT	OR	OFF	2006/05/18 18:39
S14 9	21	S148 and (glaucoma or iop)	USPAT	OR	OFF	2006/05/18 18:39
S15 0	4355	S145 and combination	US-PGPUB; USPAT	OR	OFF	2006/05/18 18:45
S15 1	2243	S150 and (ophthalmic or topical or eye)	US-PGPUB; USPAT	OR	OFF	2006/05/18 18:45
S15 2	220	S151 and (glaucoma or (ocular adj hypertension) or iop)	US-PGPUB; USPAT	OR	OFF	2006/05/18 18:46
S15 3	53	S151 and (glaucoma or (ocular adj hypertension) or iop)	USPAT	OR	OFF	2006/05/18 18:48
S15 4	8384	(glaucoma or (ocular adj hypertension) or iop)	USPAT	OR	OFF	2006/05/18 18:48
S15 5	5133	S154 and combination	USPAT	OR	OFF	2006/05/18 18:48
S15 6	54	S155 and (single adj composition)	USPAT	OR	OFF	2006/05/18 18:51
S15 7	26	S156 and ophthalmic	USPAT	OR	OFF	2006/05/18 18:56
S15 8	1776	timolol	USPAT	OR	OFF	2006/05/18 18:56
S15 9	1403	S158 and combination	USPAT	OR	OFF	2006/05/18 18:56
S16 0	1073	S159 and single	USPAT	OR	OFF	2006/05/18 18:57
S16 1	28	S159 and (single adj composition)	USPAT	OR	OFF	2006/05/18 18:59
S16 2	9016	adrenergic	USPAT	OR	OFF	2006/05/18 18:59
S16 3	160	S162 and ophthalmic	USPAT	OR	OFF	2006/05/18 19:00
S16 4	0	S163 and (single adj composition)	USPAT	OR	OFF	2006/05/18 19:00
S16 5	22	ophthalmic and (single adj composition)	USPAT	OR	OFF	2006/05/18 19:00

## EAST Search History

S16 6	10	zohreh and (single adj composition)	USPAT	OR	OFF	2006/05/18 19:03
S16 7	93	(convenience or compliance) and (single adj composition)	USPAT	OR	OFF	2006/05/18 19:05
S16 8	0	S167 and fay	USPAT	OR	OFF	2006/05/18 19:05
S16 9	0	S167 and zohreh	USPAT	OR	OFF	2006/05/18 19:05
S17 0	0	zohreh adj fay	US-PGPUB; USPAT; DERWENT	OR	OFF	2006/05/18 19:06
S17 1	1099	zohreh	US-PGPUB; USPAT; DERWENT	OR	OFF	2006/05/18 19:06
S17 2	10	S171 and (single adj composition)	US-PGPUB; USPAT; DERWENT	OR	OFF	2006/05/18 19:07
S17 3	13	brimonidine and (single adj composition)	US-PGPUB; USPAT; DERWENT	OR	OFF	2006/05/18 20:20
S17 4	374	apraclonidine	US-PGPUB; USPAT; DERWENT	OR	OFF	2006/05/18 20:20
S17 5	153	S174 and brimonidine	US-PGPUB; USPAT; DERWENT	OR	OFF	2006/05/18 20:22
S17 6	140	S175 and combination	US-PGPUB; USPAT; DERWENT	OR	OFF	2006/05/18 20:24
S17 7	98	S176 and single	US-PGPUB; USPAT; DERWENT	OR	OFF	2006/05/18 20:52
S17 8	8	S176 and (single adj composition)	US-PGPUB; USPAT; DERWENT	OR	OFF	2006/05/18 20:27
S17 9	922	bandyopadhyay	US-PGPUB; USPAT; DERWENT	OR	OFF	2006/05/18 20:53
S18 0	11	S179 and cox-2	US-PGPUB; USPAT; DERWENT	OR	OFF	2006/05/18 22:03
S18 1	303	dorzolamide	US-PGPUB; USPAT; DERWENT	OR	OFF	2006/05/18 22:03
S18 2	224	S181 and timolol	US-PGPUB; USPAT; DERWENT	OR	OFF	2006/05/18 22:03

## EAST Search History

S18 3	213	S182 and combination	US-PGPUB; USPAT; DERWENT	OR	OFF	2006/05/18 22:04
S18 4	53	S183 and merck	US-PGPUB; USPAT; DERWENT	OR	OFF	2006/05/18 22:04
S18 5	47	S184 and single	US-PGPUB; USPAT; DERWENT	OR	OFF	2006/05/18 22:04
S18 6	8	S184 and single	USPAT; DERWENT	OR	OFF	2006/05/18 22:04

This is Google's cache of <http://www.priory.com/pharmol/timolol.htm> as retrieved on Apr 19, 2006 02:37:19 GMT. Google's cache is the snapshot that we took of the page as we crawled the web. The page may have changed since that time. Click here for the [current page](#) without highlighting. This cached page may reference images which are no longer available. Click here for the [cached text](#) only. To link to or bookmark this page, use the following url: [http://www.google.com/search?q=cache:Lo-6E7T\\_YZ8J:www.priory.com/pharmol/timolol.htm+timolol+peak+plasma+concentration+&hl=en&gl=us&ct=clnk&cd=1](http://www.google.com/search?q=cache:Lo-6E7T_YZ8J:www.priory.com/pharmol/timolol.htm+timolol+peak+plasma+concentration+&hl=en&gl=us&ct=clnk&cd=1)

*Google is neither affiliated with the authors of this page nor responsible for its content.*

These search terms have been highlighted: **timolol peak plasma concentration**

# Transdermal formulation and evaluation of timolol maleate.

Saraf Swarnlata\*, Saraf S1, and Dixit V.K. 2

1Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur (CG) 492 010

2Department of Pharmaceutical Sciences, Dr. H.S. Gour V.V., Sagar, M.P.

\*e-mail: [swarnlata\\_saraf@rediffmail.com](mailto:swarnlata_saraf@rediffmail.com)

## Summary

Transdermal delivery of **timolol** maleate was tried for both reservoir as well as matrix system. The physically stable patches regarding drug contents, tensile strength, toughness and WVT were found for PVA10 and HE2 formulation. Both patches follow diffusion controlled drug permeation and high permeation with PVA10 while reservoir system follows zero order permeation kinetics.

## Introduction

**Timolol** maleate is a beta adrenoceptor-blocking agent used in treatment of cardiovascular diseases like myocardial infarction, angina pectoris, hypertension, respiratory complications and migraine. It is 8-10 times potent than propranolol 1. The main limitation of therapeutic effectiveness of **timolol** maleate is its higher frequency of drug dosing and short biological half-life, high first pass metabolism and poor bioavailability by oral route. . It is rapidly absorbed from gastrointestinal tract with **peak plasma concentration** of 5-10 ng/ ml after 1 hr<sup>2</sup>, it is metabolized up to 80% in liver with a mean half-life of 2.0-2.5 hr.<sup>3</sup>, thus necessitating frequent administration of larger doses to maintain therapeutic drug level. Therefore, To maintain effective **plasma concentration** and to avoid sub therapeutic and toxic **concentration**, a continuous delivery of **timolol** maleate is required. The transdermal route is, therefore, a better alternative, to achieve constant **plasma** level, which additionally warrants less frequent dose regime. The present study has been selected transdermal delivery system to achieve maximum therapeutic benefit.

## **MATERIALS AND METHODS**

Gift sample of **timolol** maleate (TM) was obtained from Cadila Antibiotics Ltd., Ahamdabad. Hydroxy propyl methylcellulose was procured from Warner Hindustan Ltd., Hyderabad. Dibutyl phthalate, ethyl cellulose, polyvinyl alcohol (PVA), HEPES buffer, procured from Sigma Chemical Co. St. Locus Mo, USA. All other chemicals and reagent used were of analytical reagent grade.

### *Fabrication of matrix diffusion patches*

Matrix patches were casted<sup>4</sup> on mercury using stainless steel rings having inner diameter of 1.5 cm and thickness 0.5 cm were used for holding the polymer solution on mercury surface. Two type of polymer patches were prepared; HPMC and EC combination and with PVA. The polymer solutions were prepared by dissolving HPMC 10% and EC 10 % separately in methanol- chloroform (1:1) mixture. Both solutions were mixed together in combination of 1:9, 2:8, 3:7, 4:6 and 5:5 respectively using 1% dibutyl phthalate as plasticizer. A weighed amount of drug is dispersed in polymer mixture then poured in ring placed on mercury surface in petri dish at a uniform place and solvent evaporation was controlled by conveying with funnel. After evaporation of the solvent, the film was taken out from the metal ring by sharp knife and preserve in aluminum foil. Similar procedure was adopted to prepare PVA matrix patch preparation having polymer **concentration** of 5, 10.and 15% in water with 0.5% glycerin as plasticizer.

### *Physical characterization*

Thickness of polymeric patch was measured by using a dial gauge (Mercer, England), having least count of 0.002 mm. To maintain its shape, enough hardness is required to resist independence or penetration was determined by Hall's method<sup>4</sup> and calculated as a functional weight. In order to determine the elongation as a tensile strength, the polymeric patch was pulled by means of a pulley system; weights were gradually added to the pan to increase the pulling force till the patch was broken. The elongation i.e. the distance traveled by the pointer before break of the patch was noted with the help of magnifying glass on the graph paper<sup>5</sup>, the tensile strength was calculated as kg/ cm<sup>2</sup>. The presence of moisture may not affect the hardness of patch in the normal environmental conditions, but it may affect in exaggerated conditions. The polymer patches were cut, weighed and placed in a humidity chamber maintained at 68% RH for 72 h for equilibrium. After 72 h polymer patch were taken out and weight accurately. The difference between initial and final weight was computed as percentage moisture absorbed. The water vapor transmission (WVT) from the film was calculated by Crowfold and Esmeric formula <sup>6</sup>. It was determined at 25+ 20C at 68%RH. Glass weighing bottles of equal diameter (2.5 cm) and height (5.0 cm) were used as WVT cells. A weight quantity of anhydrous calcium chloride was taken up to 10 mm height in each cell and a thin layer of silicon adhesive grease applied over the brim then patch was placed on brim and adhesive was allowed to set for 5 minutes. The cells are accurately weighed and kept in humidity chamber maintained at 68% RH for 24 h. After 24 h, the cells were again weighed

and an increase in weight was considered as a quantitative measure of the moisture transmitted through the patch. Drug distribution studies: The distribution of drug in polymer patch effect the release rate. It was studied microscopically with the help of Lietz Microscope to observe uniform distribution of drug in patch.

### ***Stability studies:***

Stability studies of all patches were performed at different storage condition by measuring tensile strength, moisture content and drug content (spectrophotometric method). The measurement were carried out by keeping the patches at different conditions of temperature 28°C, 35°C and 50°C and relative humidity of 30%, 50%, 68 % for storage period of three months at room temperature (25±10°C). The patches, which maintained uniformity, shape, toughness, drug content and flexibility at all temperature and RH, were selected for further permeation studies.

### ***Skin Preparation:***

The full thickness human cadaver skin was washed with purified water after removal of all subcutaneous fat and hairs and cut in to pieces for experimental use. The skin pieces were soaked in HEPES buffer and store in freezer at 30°C until used. Just before the experiment, it was thawed at room temperature and checked for any microscopical damage.

### ***In vitro drug permeation studies:***

A drug permeation study was carried out with drug solution in HEPES buffer pH 7.4 and stable patches through human cadaver skin using modified Keshry- Chien diffusion cells. The **concentration** of drug kept similar in drug solution in HEPES buffer and patches to compare permeation profile. The Patches and drug solution were kept on stratum corneum side of cells and this patch - skin - complex sandwiched between donor and receptor compartment. The receiving compartment contains blank 10.0 ml of HEPES buffer pH 7.4 and touches the dermal side of the skin. The whole of the assembly was kept on magnetic stirrer, which thermostatically controlled at 37± 2°C at 100 rpm. Samples were withdrawn at pre set time interval from the receiving compartment and analyzed spectrophotometrically at 294 nm using Shimadzu-1601 UV- visible spectrophotometer. The fresh buffer in receiving compartment was replaced after each withdrawal. The permeation studies determined for period of 4 h. and calculated as cumulative percent drug permeated.

### ***Results***

In present studies, the polymer and plasticizer choice for patch preparation were based on no interaction with drug and HEPES buffer with considerable stability. Various combinations of polymers hydroxy propyl methyl cellulose (HPMC) and ethyl cellulose (EC) and various



**concentration** of polyvinyl alcohol were tried for patch preparation and evaluated for physical studies (Table 1).

Formulation Code	Polymer Used	Polymer Core % w/v	Thickness Mm	Hardness Gm/cm	Tensile strength Kg/cm <sup>2</sup>	WVT gm/cm <sup>2</sup> / 4 h	Moisture absorption %
HE1	HPMC:EC	1:9	0.034	322	2.12	2.20	2.11
HE2	HPMC:EC	2:8	0.036	314	2.98	2.63	2.43
HE3	HPMC:EC	3:7	0.035	312	3.00	2.98	2.88
HE4	HPMC:EC	4:6	0.035	306	3.51	3.23	3.03
HE5	HPMC:EC	5:5	0.033	302	3.83	3.40	3.1
P5	PVA	5.0	0.031	290	2.00	3.02	2.99
P10	PVA	10	0.036	298	2.10	0.32	3.22
P15	PVA	15	0.034	302	2.54	4.01	4.00

Table 1: Physical evaluation of polymeric patch of Timilol maleate

The main physical evaluations considered for stability were WVT rate, tensile strength and % moisture absorption and drug content. The polymer patch prepared with combination in the ratio of 2:8 HPMC and EC (HE2), PVA of 10% w/v (P10) were found to be satisfactory at all temperatures and relative humidity. On the basis of physical and stability studies, the patches HE2 and PVA10 were considered for permeation studies. The in- vitro permeation studies of drug solution and patches were performed to observe permeation profile. The permeation profile of both solution and patches were compared

### Discussion

The in- vitro stability studies of all patches were performed in terms of stability against storage conditions and aging effect, because TM is a drug used for long therapy to maintain its therapeutic effect especially when used as antihypertensive agent. The physical characterization like tensile strength, moisture absorption and WVT rate and drug content were main parameter for stability studies, which revealed no appreciable changes occurred in patches (HE2 & PVA10) at normal storage conditions (25°C±1). The drug solution permeation profile suggests that it followed Fick's law of diffusion. Linear relationship between cumulative percent drug permeated verses time indicate zero order permeation of drug through human cadaver skin with lag time 35 minutes. The transdermal permeability coefficient of TM was calculated to be  $323 \times 10^{-5} \pm 0.02 \text{ cm}^2/\text{h}$  from the steady state portion of the curve (Fig.1).




Fig.1: In-vitro permeation profile of timolol maleate from drug solution through human cadaver skin.

The permeation profile of drug from both patches HE2 and PVA10 when plotted, between permeation data against square root of time shows linear relationship indicating drug permeation followed Higuchi equation (Fig.2).




Fig.2 : In-vitro permeation profiles of timolol maleate from selected matrix diffusion patches through human cadaver skin.  
HE<sub>2</sub> (■), PVA<sub>10</sub> (▲).

The permeation profile data of patches were plotted in log values with time, the slope value comes near to  $0.49 \pm 0.01SD$  ( $\sim 0.5$ ), suggesting drug permeation is controlled by diffusion within the matrix rather than by skin.

When we compare both patches, the PVA10 system provide higher  $1.589 \pm 0.20 SD$  % drug/cm<sup>2</sup> of permeation rather than HE<sub>2</sub>, i.e.,  $0.987 \pm 0.20$  % drug/cm<sup>2</sup> in 4h of period.


## Conclusion

The studies suggest that both reservoir as well as matrix system of transdermal delivery of TM is possible. The reservoir system followed zero order while the matrix system followed first order release profile. Among both matrix systems PVA10 patch have more permeability than HE<sub>2</sub> patch.

## References

1. Napolian, L. A., Smith, R. L., Proceed. Int. Symp, Controlled Release Bioact. Mater., 17, Controlled Released Society Inc. USA 1990, Abst. No. D220.
2. Remington Pharmaceutical Sciences, 18th Ed., Mark Publishing Company, Pennsylvania, 1990, P 1676.
3. Vermeji P. J., Pharm. Pharmacol, 1978, 50,53.
4. Sciarria, J. J., Patel, S. P., J. Pharm. Sci., 1975, 64, 128.
5. Allen, D. J., DeHerco J. D., Kwan, K. C., J. Pharm. Sci., 1972, 61, 107.
6. Crawford, R. R., Esmerian, O. K., J. Pharm. Sci., 1971, 60, 314.


First Published February 4th 2006



All pages copyright ©Priory Lodge Education Ltd 1994-2006.



A service of the National Library of Medicine  
and the National Institutes of Health



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search  for

Limits Preview/Index History Clipboard Details

About Entrez  
NCBI Toolbar

Text Version

Entrez PubMed  
Overview  
Help | FAQ  
Tutorials  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
Special Queries  
LinkOut  
My NCBI

Related Resources  
Order Documents  
NLM Mobile  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

**Note:** Performing your original search, *half life timolol*, in PubMed will retrieve 38 citations.

Display  Show  Sort by  Send to

All: 1 Review: 0

☐ 1: Br J Clin Pharmacol. 1997 Mar;43(3):301-8.

[Related Articles, Links](#)

## **A prospective study of the effects of prolonged timolol therapy on alpha- and beta-adrenoceptor and angiotensin II receptor mediated responses in normal subjects.**

**Ferro A, Hall JA, Dickerson JE, Brown MJ.**

Clinical Pharmacology Unit, University of Cambridge, Addenbrooke's Hospital.

**AIMS:** Long-term treatment with beta 1-selective adrenergic antagonists gives rise to cross-sensitisation of cardiac beta 2-adrenoceptor responses, with no corresponding alteration in beta 1-adrenoceptor responses. We performed a prospective randomised double-blind placebo-controlled cross-over study of the effects of nonselective beta-blockade with timolol on alpha-adrenergic and angiotensin II receptor mediated responses in normal subjects. We also wished to study the time course of beta 1- and beta 2-adrenergic responses after withdrawal of timolol. **METHODS:** Six healthy males received timolol 10 mg twice daily or placebo for 14 days. On day 11 of treatment, vascular alpha 1-, alpha 2- and angiotensin II receptor responses were assessed by measuring the blood pressure increases in response to intravenous phenylephrine, alpha-methylnoradrenaline and angiotensin amide respectively, following one dose of timolol 10 mg (to block the beta-adrenergic effects of phenylephrine and alpha-methylnoradrenaline). Both systolic and diastolic blood pressure increased in response to each of these drugs, but these increases were not different on timolol treatment or placebo. Following cessation of treatment with timolol or placebo, beta 1- and beta 2-adrenoceptor mediated responses were assessed by measuring the heart rate responses to treadmill exercise and intravenous salbutamol infusion respectively. Half each of the subjects underwent this 2 days and 3 days respectively, after the end of treatment. **RESULTS:** Both exercise-induced and salbutamol-induced tachycardia were not different following placebo or 3 days following the end of timolol treatment. However, 2 days following timolol treatment, both were attenuated; the reduction in salbutamol-induced tachycardia was significant, whilst the reduction in exercise tachycardia did not reach statistical significance. We also measured metabolic responses to exercise and to salbutamol infusion. Exercise induced a rise in plasma potassium and noradrenaline. Salbutamol produced a fall in plasma potassium, a rise in plasma glucose and insulin and also a rise in plasma noradrenaline. All of these changes were not different following placebo or 3 days after the end of timolol treatment; by contrast, 2 days following timolol treatment, all were significantly attenuated, with the

exception of the rise in plasma glucose. In addition, the rise in both plasma glucose and insulin in response to an oral load of 75 g glucose were not different post-placebo, 2 or 3 days post-timolol. CONCLUSIONS: These results show that, following 14 days of nonselective beta-adrenoceptor blockade with timolol, there is evidence of residual beta-adrenoceptor blockade 2 days after drug withdrawal; this finding is in contrast with the known plasma profile of timolol (half-life 3-6 hours), but is consistent with our previous observations of the slow speeds of association and dissociation of timolol with beta-adrenoceptors in vitro. There is no evidence, in this study, of beta-adrenergic sensitisation following timolol withdrawal, nor of cross-regulation of vascular alpha 1-, alpha 2- or angiotensin II receptors in response to nonselective beta-adrenoceptor blockade.

Publication Types:

- [Clinical Trial](#)
- [Randomized Controlled Trial](#)

PMID: 9088585 [PubMed - indexed for MEDLINE]

---

Display  ☒ Show  ☒ Sort by  ☒ Send to  ☒

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
[Department of Health & Human Services](#)  
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

May 9 2006 14:13:00

This is **G o o g l e**'s cache of <http://redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi?CARD=APRD00229.txt> as retrieved on May 14, 2006 11:42:09 GMT.

**G o o g l e**'s cache is the snapshot that we took of the page as we crawled the web.

The page may have changed since that time. [Click here](#) for the current page without highlighting.

This cached page may reference images which are no longer available. [Click here](#) for the cached text only.

To link to or bookmark this page, use the following url: [http://www.google.com/search?](http://www.google.com/search?q=cache:Ht_1PlvWNlEJ:redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi%3FCARD%3DAPRD00229.txt+half+life+timolol&hl=en&gl=us&ct=clnk&cd=17)

[q=cache:Ht\\_1PlvWNlEJ:redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi%3FCARD%3DAPRD00229.txt+half+life+timolol&hl=en&gl=us&ct=clnk&cd=17](http://www.google.com/search?q=cache:Ht_1PlvWNlEJ:redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi%3FCARD%3DAPRD00229.txt+half+life+timolol&hl=en&gl=us&ct=clnk&cd=17)

*Google is neither affiliated with the authors of this page nor responsible for its content.*

These search terms have been highlighted: **half life timolol**

# DrugBank


[Home](#) [Browse](#) [PharmaBrowse](#) [ChemQuery](#) [Text Query](#) [SeqSearch](#) [Data](#)  
[Extractor](#) [Download](#)

Search DrugBank for:

## DrugBank Timolol (APRD00229)

for

Creation Date	2005/6/27 6:31:0 GMT
Last Update	Mar 30, 2006
Accession Number	APRD00229
Generic Name	<b>Timolol</b>
Brand Names/Synonyms	<ol style="list-style-type: none"><li>1. Apo-Timol</li><li>2. Apo-Timop</li><li>3. Aquanil</li><li>4. Betim</li><li>5. Betimol</li><li>6. Blocadren</li><li>7. Istalol</li><li>8. Novo-Timol</li><li>9. Proflax</li><li>10. Temserin</li><li>11. Tenopt</li><li>12. Tim-AK</li><li>13. Timacar</li><li>14. Timacor</li><li>15. Timololum [INN-Latin]</li><li>16. Timopic</li></ol>

	17. Timoptic 18. Timoptic in Ocudose 19. Timoptic-XE 20. Timoptol
Brand Name Mixtures	1. Combigan (Brimonidine Tartrate + <b>Timolol Maleate</b> ) 2. Cosopt -(2%/0.5% Oph Dps) (Dorzolamide Hydrochloride + <b>Timolol Maleate</b> ) 3. Timolide Tab (Hydrochlorothiazide + <b>Timolol Maleate</b> ) 4. Timpilo 2 (Pilocarpine Hydrochloride + <b>Timolol Maleate</b> ) 5. Timpilo 4 (Pilocarpine Hydrochloride + <b>Timolol Maleate</b> ) 6. Xalacom (Latanoprost + <b>Timolol Maleate</b> )
Chemical IUPAC Name	1-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]-3-tert-butylamino-propan-2-ol
Chemical Formula	C <sub>13</sub> H <sub>24</sub> N <sub>4</sub> O <sub>3</sub> S
Chemical Structure	
CAS Registry Number	26839-75-8
InChi Identifier	InChI=1/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1
KEGG Compound ID	C07141
PubChem ID	SID:175467
ChEBI ID	Not Available
PharmGKB ID	PA451690
HET ID	Not Available
SwissProt ID	Not Available
GenBank ID	Not Available
Drug ID Number [DIN]	00812455
RxList Link	<b>Timolol</b>
FDA Label	<a href="#">Click for FDA Label (pdf)</a>
Material Safety Data Sheet (MSDS)	<a href="#">Click Here for MSDS File (pdf)</a>
Synthesis Reference	Wasson et al., J. Med. Chem. 15, 615 (1972)
Molecular Weight	316.421 g/mol

Melting Point	201.5-202.5 °C
H <sub>2</sub> O Solubility	2.74 mg/mL
State	Solid
LogP/Hydrophobicity	1.761
pKa/Isoelectric Point	3.9
NMR Spectrum	Not Available
Mass Spectrum	Not Available
MOL File Image	<a href="#">View 2D Structure</a>
MOL File Text	<a href="#">Click Here for MOL File</a>
SDF File	<a href="#">Click Here for SDF File</a>
PDB File Calculated Image	<a href="#">View 3D Structure</a>
PDB File Calculated Text	<a href="#">Click Here for PDB File</a>
PDB Experimental ID	Not Available
Smiles String	<chem>CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O</chem>
Drug Type	Approved Drug
Drug Category	<ul style="list-style-type: none"> <li>■ Antihypertensive Agents</li> <li>■ Anti-Arrhythmia Agents</li> <li>■ Adrenergic beta-Antagonists</li> <li>■ ATC:C07AA06</li> <li>■ ATC:S01ED01</li> </ul>
Indication	In its oral form it is used to treat high blood pressure and prevent heart attacks, and occasionally to prevent migraine headaches. In its ophthalmic form it is used to treat open-angle and occasionally secondary glaucoma.
Pharmacology	Similar to propranolol and nadolol, <b>timolol</b> is a non-selective, beta-adrenergic receptor antagonist. <b>Timolol</b> does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity, but does possess a relative high degree of lipid solubility. <b>Timolol</b> , when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage.
Mechanism of Action	Like propranolol and nadolol, <b>timolol</b> competes with adrenergic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle and beta(2)-receptors in the bronchial and vascular smooth muscle. Beta(1)-receptor blockade results in a decrease in resting and exercise heart rate and cardiac output, a decrease in both systolic and diastolic blood pressure, and, possibly, a reduction in reflex orthostatic hypotension. Beta(2)-blockade results in an increase in peripheral vascular resistance. The exact mechanism whereby <b>timolol</b> reduces ocular pressure is still not known. The most likely action is by decreasing the secretion of aqueous humor.



Absorption	Bioavailability is about 60%
Toxicity	LD <sub>50</sub> =1190 mg/kg (oral, mice), LD <sub>50</sub> =900 mg/kg (oral, rat). Symptoms of overdose include drowsiness, vertigo, headache, and atrioventricular block.
Protein Binding	~10%
Biotransformation	Primarily hepatic (80%) via the cytochrome P450 2D6 isoenzyme.
Half Life	2.5-5 hours
Dosage Forms	<ul style="list-style-type: none"> <li>■ Drops</li> <li>■ Liquid</li> <li>■ Solution</li> <li>■ Solution (long-acting)</li> <li>■ Tablet</li> </ul>
Patient Information	Click for Patient Information
Interactions	Click for Interactions
Contraindications	Click for Contraindications
Drug Reference	<a href="http://www.drugs.com/cons/Timolol.html">http://www.drugs.com/cons/Timolol.html</a> <a href="http://www.rxlist.com/cgi/generic3/timololgfs.htm">http://www.rxlist.com/cgi/generic3/timololgfs.htm</a> <a href="http://www.inchem.org/documents/pims/pharm/timolol.htm">http://www.inchem.org/documents/pims/pharm/timolol.htm</a>
Phase 1 Metabolizing Enzyme	CYP2D6
Phase 1 Metabolizing Enzyme Sequence	<p>&gt; sp P10635 CP2D6_HUMAN Cytochrome P450 2D6</p> <p>MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ  LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF  LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK  AVSNVIASLTGRRFEYDDPRFLRLDLAQEGLKEESGFLREVLNAVVPVLLHIPALAGKV  LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA  DLFSAGMVTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI  HEVQRFQDIVPLGMTHMTSRDIEVQGFRI PKGTTLITNLSSVLKDEAVWEKPFRFHPEHF  LDAQGHFVKPEAFLPFSAGRRACLGEPLARMEFLFFTSLLQHFSFSVPTGQPRPSHHGV  FAFLVSPSPYELCAVPR</p>
Phase 1 Metabolizing Enzyme SwissProt ID	CP2D6_HUMAN
<b>Drug Target 1</b>	
Drug Target 1 Name	Beta-1 Adrenergic Receptor
Drug Target 1 Gene Name	ADRB1
Drug Target 1 Synonyms	<ol style="list-style-type: none"> <li>1. Beta-1 adrenergic receptor</li> <li>2. Beta-1 adrenoceptor</li> <li>3. Beta-1 adrenoreceptor</li> </ol>
Drug Target 1 Protein Sequence	<p>&gt; Beta-1 Adrenergic Receptor</p> <p>MGAGVLVLGASEPGNLSSAAPLPDGAATAARLLVPASPPASLLPPASESPEPLSQWQTAG  MGLLMALIVLLVAGNVLVIVIAIAKTPLRLTLTNLFIMSLASADLVMGLLVVPFGATIVV  WGRWEYGSFFCELWTSVDVLCVTASIELTCVIALDRYLAITSPPRYQSLLTRARARGLVC  TVWAI SALVSFLPILMHWWRAESDEARRCYNDPKCCDFVTNRAYAIASSVVSFYVPLCIM</p>

	AFVYLRVFREAQKQVKKIDSCERRFLGGPARPPSPSPSPVPAPAPPPGPPRPAAAAATAP LANGRAGKRRPSRLVALREQKALKTLGIIMGVFTLCWLPFFLANVVKAHFHRELVPDRLFV FFNWLGYANSAFNPIIYCRSPDFRKAQRLCCARRAARRRHATHGDRPRASGCLARPGP PPSPGAASDDDDDDVVGATPPARLLEPWAGCNGGAAADSSSLDEPCRPGFASESKV
Drug Target 1 Number of Residues	477
Drug Target 1 Molecular Weight	51323 g/mol
Drug Target 1 Theoretical pI	9.03
Drug Target 1 GO Classification	>>> Function: signal transducer activity Function: receptor activity Function: transmembrane receptor activity Function: G-protein coupled receptor activity Function: rhodopsin-like receptor activity Function: amine receptor activity Function: adrenoceptor activity Function: beta-adrenergic receptor activity Function: beta1-adrenergic receptor activity    >>> Process: cellular process Process: cell communication Process: signal transduction Process: cell surface receptor linked signal transduction Process: G-protein coupled receptor protein signaling pathway    >>> Component: cell Component: membrane Component: integral to membrane
Drug Target 1 General Function	Receptor activity and cell communication
Drug Target 1 Specific Function	Beta-adrenergic receptors mediate the catecholamine- induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximatively equal affinity
Drug Target 1 Pathway	Not Available
Drug Target 1 Reaction	Not Available
Drug Target 1 Pfam Domain Function	PF00001 7tm_1
Drug Target 1 Signals	None
Drug Target 1 Transmembrane Regions	60-83 97-120 132-155 176-199

	222-245 326-349 357-380				
Drug Target 1 Essentiality	Not Available				
Drug Target 1 GenBank ID Protein	178200				
Drug Target 1 SwissProt ID	ADRB1_HUMAN (P08588)				
Drug Target 1 PDB ID	Not Available				
Drug Target 1 3D Structure Text	Not Available				
Drug Target 1 3D Structure Image	Not Available				
Drug Target 1 Cellular Location	Integral membrane protein				
Drug Target 1 Gene Sequence	> Beta-1 Adrenergic Receptor, 1434 bp ATGGGCGCGGGGGTGTCTGTCCTGGGCGCCTCCGAGCCCGGTAACCTGTCTGTCGGCCGCA CCGCTCCCCGACGGCGCGGCCACCGCGGCGCGGCTGCTGGTGCCCGCGTCGCCGCCCGCC TCGTTGCTGCCTCCCGCCAGCGAAAGCCCCGAGCCGCTGTCTCAGCAGTGGACAGCGGGC ATGGGTCTGCTGATGGCGCTCATCGTGCTGCTCATCGTGGCGGGCAATGTGCTGGTGATC GTGGCCATCGCCAAGACGCCGCGGCTGCAGACGCTCACCAACCTCTTCATCATGTCCCTG GCCAGCGCCGACCTGGTCATGGGGCTGCTGGTGGTGCCGTTCCGGGGCCACCATCGTGGTG TGGGGCCGCTGGGAGTACGGCTCCTTCTTCTGCGAGCTGTGGACCTCAGTGGACGTGCTG TGCGTGACGGCCAGCATCGAGACCCTGTGTGTCAATTGCCCTGGACCGCTACCTCGCCATC ACCTCGCCCTTCCGCTACCAGAGCCTGCTGACGCGCGCGCGGGCGCGGGGCCTCGTGTGC ACCGTGTGGGCCATCTCGGCCCTGGTGTCTTCTGCCCATCCTCATGCACTGGTGGCGG GCGGAGAGCGACGAGGCGCGCCGCTGCTACAACGACCCCAAGTGCTGCGACTTCGTCACC AACGGGGCCTACGCCATCGCCTCGTCCGTAGTCTCCTTCTACGTGCCCCCTGTGCATCATG GCCTTCGTGTACCTGCGGGTGTTCCGCGAGGCCCAGAAGCAGGTGAAGAAGATCGACAGC TGCGAGCGCCGTTTCTCGGCGGGCCAGCGCGGCCCGCCCTCGCCCTCGCCCTCGCCCGTC CCGCGCCCCGCGCCGCCCGCCGACCCCCGCGCCCCCGCCGCCGCCGCCACCGCCCCG CTGGCCAACGGGCGTGCGGGTAAGCGGCGGCCCTCGCGCCTCGTGGCCCTACGCGAGCAG AAGGCGCTCAAGACGCTGGGCATCATATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTC TTCTTGCCAAACGTGGTGAAGGCCTTCACCGCGAGCTGGTGCCCGACCGCCTCTTCGTC TTCTTCAACTGGCTGGGCTACGCCAACTCGGCCTTCAACCCATCATCTACTGCCGCAGC CCGACTTCCGCAAGGCCTTCCAGGGACTGCTCTGCTGCGCGCGCAGGGCTGCCCCGCCG CGCCACGCGACCCACGGAGACCGGCCGCGCCCTCGGGCTGTCTGGCCCGGCCGACCC CCGCCATCGCCCCGGGGCCGCTCGGACGACGACGACGATGTGCTCGGGGCCACGCCG CCGCGCGCCTGCTGGAGCCCTGGGCGGCTGCAACGGCGGGGCGGCGGACAGCGAC TCGAGCCTGGACGAGCCGTGCCGCCCGGCTTCGCCTCGGAATCCAAGGTGTAG				
Drug Target 1 GenBank ID Gene	J03019				
Drug Target 1 Chromosome Location	Chromosome:10				
Drug Target 1 Locus	10q24-q26				
	refSNP ID	Function	Alleles	Amino Acids	Allele Frequencies
		Validation	Position	Position	
					African: A 0.992 G 0.008

Drug Target 1 SNPs	rs1801252	nonsynonymous	A-G	Not Available	European: Not Available Asian: A 1 G 0
		[2+4+5]	256		
	rs1801253	nonsynonymous	C-G	Not Available	African: G 0.408 C 0.592 European: G 0.317 C 0.683 Asian: G 0.2 C 0.8
		[2+4+5]	256		
	rs180897	nonsynonymous	C-T	Not Available	African: C 1 T 0 European: C 1 T 0 Asian: C 1 T 0
		5	201		

Drug Target 1 References	2825170 10477438 10212248 11052857 11854867
--------------------------	---

**Drug Target 2**

Drug Target 2 Name	Beta-2 Adrenergic Receptor
Drug Target 2 Gene Name	ADRB2
Drug Target 2 Synonyms	1. Beta-2 adrenergic receptor 2. Beta-2 adrenoceptor 3. Beta-2 adrenoreceptor
Drug Target 2 Protein Sequence	> Beta-2 Adrenergic Receptor MGQPGNGSAFLAPNRSHAPDHDVTQQRDEVWVVGMGIVMSLIVLAIVFGNVLVITAIK FERLQTVTNFYFITSACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTAS IETLCVIAVDYFAITSFPHYQSLLTKNKARVILMVWIVSGLTSFLPIQMHWRATHQE AINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAQRQLQKIDKSEGRF HVQNLSQVEQDGRGTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQD NLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGNT GEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPDNDIDSQGRNCSTNDSLL
Drug Target 2 Number of Residues	413
Drug Target 2 Molecular Weight	46557 g/mol
Drug Target 2 Theoretical pI	7.44
Drug Target 2 GO Classification	>>> Function: signal transducer activity Function: receptor activity Function: transmembrane receptor activity Function: G-protein coupled receptor activity Function: rhodopsin-like receptor activity Function: amine receptor activity Function: adrenoceptor activity Function: beta-adrenergic receptor activity Function: beta2-adrenergic receptor activity    >>> Process: cellular process

	Process: cell communication Process: signal transduction Process: cell surface receptor linked signal transduction Process: G-protein coupled receptor protein signaling pathway    >>> Component: cell Component: membrane Component: integral to membrane
Drug Target 2 General Function	Receptor activity and cell communication
Drug Target 2 Specific Function	Beta-adrenergic receptors mediate the catecholamine- induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine
Drug Target 2 Pathway	Not Available
Drug Target 2 Reaction	Not Available
Drug Target 2 Pfam Domain Function	PF00001 7tm_1
Drug Target 2 Signals	None
Drug Target 2 Transmembrane Regions	35-58 72-95 107-129 151-174 197-220 275-298 306-329
Drug Target 2 Essentiality	Not Available
Drug Target 2 GenBank ID Protein	29371
Drug Target 2 SwissProt ID	ADRB2_HUMAN (P07550)
Drug Target 2 PDB ID	Not Available
Drug Target 2 3D Structure Text	Not Available
Drug Target 2 3D Structure Image	Not Available
Drug Target 2 Cellular Location	Integral membrane protein
	> Beta-2 Adrenergic Receptor, 1242 bp ATGGGGCAACCCGGGAACGGCAGCGCCTTCTTGCTGGCACCCAATAGAAGCCATGCGCCG GACCACGACGTCACGCAGCAAAGGGACGAGGTGTGGGTGGTGGGCATGGGCATCGTCATG TCTCTCATCGTCCTGGCCATCGTGTTTGGCAATGTGCTGGTCATCACAGCCATTGCCAAG TTCGAGCGTCTGCAGACGGTCACCAACTACTTCATCACTTCACTGGCCTGTGCTGATCTG

Drug Target 2 Gene Sequence	GTCATGGGCCTGGCAGTGGTGGCCCTTTGGGGCCGCCCATATTCTTATGAAAATGTGGACT TTTGGCAACTTCTGGTGCAGTTTTGGACTTCCATTGATGTGCTGTGCGTCACGGCCAGC ATTGAGACCCTGTGCGTGATCGCAGTGGATCGCTACTTTGCCATTACTTCACCTTTCAAG TACCAGAGCCTGCTGACCAAGAATAAGGCCCGGGTGATCATTCTGATGGTGTGGATTGTG TCAGGCCTTACCTCCTTCTTGCCCATTCAGATGCACTGGTACCGGGGCCACCCACCAGGAA GCCATCAACTGCTATGCCAATGAGACCTGCTGTGACTTCTTCACGAACCAAGCCTATGCC ATTGCCTCTTCCATCGTGTCCCTTCTACGTTCCCCTGGTGATCATGGTCTTCGTCTACTCC AGGGTCTTTTACAGGAGGCCAAAAGGCAGCTCCAGAAGATTGACAAATCTGAGGGCCGCTTC CATGTCCAGAACCTTAGCCAGGTGGAGCAGGATGGGCGGACGGGGCATGGACTCCGCAGA TCTTCCAAGTTCTGCTTGAAGGAGCACAAAGCCCTCAAGACGTTAGGCATCATCATGGGC ACTTTCACCCTCTGCTGGCTGCCCTTCTTCATCGTTAACATTGTGCATGTGATCCAGGAT AACCTCATCCGTAAGGAAGTTTACATCCTCCTAAATTGGATAGGCTATGTCAATTCTGGT TTCAATCCCCTTATCTACTGCCGGAGCCCAGATTTTCAAGATTGCCTTCCAGGAGCTTCTG TGCCTGCGCAGGTCTTCTTTGAAGGCCTATGGGAATGGCTACTCCAGCAACGGCAACACA GGGGAGCAGAGTGGATATCACGTGGAACAGGAGAAAGAAAATAAACTGCTGTGTGAAGAC CTCCAGGCACGGAAGACTTTGTGGGCCATCAAGGTACTGTGCCTAGCGATAACATTGAT TCACAAGGGAGGAATTGTAGTACAAATGACTCACTGCTGTAA				
Drug Target 2 GenBank ID Gene	Y00106				
Drug Target 2 Chromosome Location	Chromosome:5				
Drug Target 2 Locus	5q31-q32				
Drug Target 2 SNPs	refSNP ID	Function Validation	Alleles Position	Amino Acids Position	Allele Frequencies
	rs1042714	nonsynonymous	C-G	Glu[E]-Gln[Q]	African: G 0.175 C 0.825
		[1+2+4+5]	329	27	European: G 0.467 C 0.533 Asian: G 0.101 C 0.899
	rs1042713	nonsynonymous	A-G	Gly[G]-Arg[R]	African: G 0.525 A 0.475
		[2+4+5]	296	16	European: G 0.675 A 0.325 Asian: G 0.539 A 0.461
	rs1800888	nonsynonymous	C-T	Ile[I]-Thr[T]	African: C 1 T 0
		[1+2+5]	741	164	European: C 0.992 T 0.008 Asian: C 1 T 0
	rs1042718	synonymous	A-C	Arg[R]-Gly[G]	African: C 0.65 A 0.35
		[1+2+4+5]	773	175	European: C 0.808 A 0.192 Asian: C 0.568 A 0.432
	rs1042717	synonymous	A-G	Leu[L]-Leu[L]	Not Available
		[1+2+4]	502	84	
	rs1042720	synonymous	A-G/T	Leu[L]-Leu[L]	Not Available
		[1+4]	201	413	
	rs1042719	synonymous	C-G	Gly[G]-Gly[G]	African: G 0.643 C 0.357
		[1+2]	1303	351	European: Not Available Asian: G 0.477 C 0.523
	rs3730182	synonymous	C-T	Thr[T]-Thr[T]	Not Available
		[1]	102	393	
	rs1801704	untranslated	C-T	Not Available	African: C 0.138 T 0.862 European: Not Available

		[1+2+4]	231		Asian: C 0.048 T 0.952
	rs1042711	untranslated	C-T	Not Available	African: C 0.123 T 0.877
		[1+2+4]	204		European: Not Available
	rs3729943	nonsynonymous	C-G	Cys[C]-Ser[S]	Asian: C 0.054 T 0.946
		5	151	220	Not Available
	rs3729944	synonymous	C-T	His[H]-His[H]	African: T 1 C 0
		5	151	390	European: T 1 C 0
	Asian: T 1 C 0				
Drug Target 2 References	3033609 3025863 3026848 2823249 3034889 2831218 2540197 11146000 8383511 7915137 7706471				
Organisms Affected	Humans and other mammals				

Contact: **David Wishart** (Last Update: Mar 30, 2006)

This is Google's cache of [http://www.rxlist.com/cgi/generic2/dorzol\\_cp.htm](http://www.rxlist.com/cgi/generic2/dorzol_cp.htm) as retrieved on May 10, 2006 00:30:42 GMT. Google's cache is the snapshot that we took of the page as we crawled the web. The page may have changed since that time. Click here for the [current page](#) without highlighting. This cached page may reference images which are no longer available. Click here for the [cached text only](#). To link to or bookmark this page, use the following url: [http://www.google.com/search?q=cache:pMTKuyZ7dHEJ:www.rxlist.com/cgi/generic2/dorzol\\_cp.htm+peak+plasma+concentration+timolol&hl=en&gl=us&ct=clnk&cd=2](http://www.google.com/search?q=cache:pMTKuyZ7dHEJ:www.rxlist.com/cgi/generic2/dorzol_cp.htm+peak+plasma+concentration+timolol&hl=en&gl=us&ct=clnk&cd=2)

Google is neither affiliated with the authors of this page nor responsible for its content.

These search terms have been highlighted: **peak plasma concentration timolol**



**RxList** The Internet Drug Index

[Disclaimer](#)

[RxBoard](#)

[Alternatives](#)

[Top 200](#)

[Advanced Search](#)

[Online Pharm](#)

## Dorzolamide / Timolol Maleate

[Description](#)

[Clinical Pharmacology](#)

[Indications & Dosage](#)

[Side Effects & Drug Interactions](#)

[Warnings & Precautions](#)

[Overdosage Contraindications](#)

[Patient Information](#)

### CLINICAL PHARMACOLOGY

[Drug-Search](#)

#### Mechanism of Action

**WebMD**

**Health Source**  
[my.webmd.com](http://my.webmd.com)

▶ **Newly Diagnosed?:**

[Start Here](#)

▶ **Take A Quiz:**

[Test Your Knowledge](#)

▶ **Questions Answered:**

[Symptoms, Treatments, More](#)

▶ **Find it Fast:**

[WebMD Medical Library](#)

☑ **Breaking Health**

**Alerts:**

[Sign Up Here](#)

Can't Find What You Need?

Search WebMD Health:

[Go!](#)

COSOPT\*(Dorzolamide/Timolol Maleate) is comprised of two components: dorzolamide hydrochloride and **timolol** maleate. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma, by reducing aqueous humor secretion. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage.

advertisement

ATTENTION PHYSICIANS

**Need Help?**

Try Medscape.com's Specialty Services

- Medline Access
- Conference Coverage
- Free CME

[Click here](#) **Medscape**

Dorzolamide hydrochloride is an inhibitor of human carbonic anhydrase II. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor



## Advertisements

**Featured Centers**

- [Save on your Rx?](#)
- [Medicare Drug Benefit](#)
  - [Nighttime GERD](#)
  - [Bipolar Rx Info](#)
- [Migraine Therapy](#)
- [Heart Failure Device](#)
- [Epilepsy Assessment](#)

**News From WebMD**

- [Company Issues Pacemaker Malfunction Warning](#)
- [Deaths Seen With Fentanyl Narcotic Pain Patch](#)
- [FDA Reviews Adult Antidepressant-Suicide Link](#)

secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. **Timolol** maleate is a  $\beta_1$  and  $\beta_2$  (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. The combined effect of these two agents administered as COSOPT b.i.d. results in additional intraocular pressure reduction compared to either component administered alone, but the reduction is not as much as when dorzolamide t.i.d. and **timolol** b.i.d. are administered concomitantly (see **Clinical Studies** below).

**Pharmacokinetics/Pharmacodynamics*****Dorzolamide Hydrochloride***

When topically applied, dorzolamide reaches the systemic circulation. To assess the potential for systemic carbonic anhydrase inhibition following topical administration, drug and metabolite concentrations in RBCs and **plasma** and carbonic anhydrase inhibition in RBCs were measured. Dorzolamide accumulates in RBCs during chronic dosing as a result of binding to CA-II. The parent drug forms a single N-desethyl metabolite, which inhibits CA-II less potently than the parent drug but also inhibits CA-I. The metabolite also accumulates in RBCs where it binds primarily to CA-I. **Plasma** concentrations of dorzolamide and metabolite are generally below the assay limit of quantitation (15nM). Dorzolamide binds moderately to **plasma** proteins (approximately 33%).

Dorzolamide is primarily excreted unchanged in the urine; the metabolite also is excreted in urine. After dosing is stopped, dorzolamide washes out of RBCs nonlinearly, resulting in a rapid decline of drug concentration initially, followed by a slower elimination phase with a half-life of about four months.

To simulate the systemic exposure after long-term topical ocular administration, dorzolamide was given orally to eight healthy subjects for up to 20 weeks. The oral dose of 2 mg b.i.d. closely approximates the amount of drug delivered by topical ocular administration of dorzolamide 2% t.i.d. Steady state was reached within 8 weeks. The inhibition of CA-II and total carbonic anhydrase activities was below the degree of inhibition anticipated to be necessary for a pharmacological effect on renal function and respiration in healthy individuals.

***Timolol Maleate***

In a study of **plasma** drug concentrations in six subjects, the systemic exposure to **timolol** was determined following twice daily topical administration of **timolol** maleate ophthalmic solution 0.5%. The mean peak plasma concentration following morning dosing was 0.46 ng/mL.

**Clinical Studies**

Clinical studies of 3 to 15 months duration were conducted to compare the IOP-lowering effect over the course of the day of COSOPT b.i.d. (dosed morning and bedtime) to individually- and concomitantly-administered 0.5% **timolol** (b.i.d.) and 2.0% dorzolamide (b.i.d. and t.i.d.). The IOP-lowering effect of COSOPT b.i.d. was greater (1-3 mmHg) than that of monotherapy with either 2.0% dorzolamide t.i.d. or 0.5% **timolol** b.i.d. The IOP-lowering effect of COSOPT b.i.d. was approximately 1 mmHg less than that of concomitant therapy with 2.0% dorzolamide t.i.d. and 0.5% **timolol** b.i.d.

Open-label extensions of two studies were conducted for up to 12 months. During this period, the IOP-lowering effect of COSOPT b.i.d. was consistent during the 12 month follow-up period.

▲ ▢ ▹ ▸

This Page Last Updated 11/01/2005

**Return to Top**  **Search Medical Dictionary**  **FAQ/Patient Monograph** 

---

[RxList Home](#)   [Contact RxList](#)   [About RxList](#)   [Terms & Policies](#)   [Privacy Policy](#)

[WebMD®](#) | [Medscape®](#) | [eMedicineHealth®](#) | [MedicineNet®](#)

Copyright © 2006 by RxList Inc.

This is Google's cache of <http://www.inchem.org/documents/pims/pharm/timolol.htm> as retrieved on May 13, 2006 08:59:58 GMT.

Google's cache is the snapshot that we took of the page as we crawled the web.

The page may have changed since that time. Click here for the [current page](#) without highlighting.

This cached page may reference images which are no longer available. Click here for the [cached text only](#).

To link to or bookmark this page, use the following url: <http://www.google.com/search?q=cache:f5QnmyjkabIJ:www.inchem.org/documents/pims/pharm/timolol.htm+peak+plasma+concentration+timolol&hl=en&gl=us&ct=clnk&c>

*Google is neither affiliated with the authors of this page nor responsible for its content.*

These search terms have been highlighted: **peak plasma concentration timolol**



# Timolo

## 1. NAME

### 1.1 Substance

### 1.2 Group

### 1.3 Synonyms

### 1.4 Identification numbers

#### 1.4.1 CAS number

#### 1.4.2 Other numbers

### 1.5 Brand names, Trade names

### 1.6 Manufacturers, Importers

## 2. SUMMARY

### 2.1 Main risks and target organs

### 2.2 Summary of clinical effects

### 2.3 Diagnosis

### 2.4 First aid measures and management principles

## 3. PHYSICO-CHEMICAL PROPERTIES

### 3.1 Origin of the substance

### 3.2 Chemical structure

### 3.3 Physical properties

#### 3.3.1 Properties of the substance

### 3.3.2 Properties of the locally available formulation

## 3.4 Other characteristics

### 3.4.1 Shelf-life of the substance

### 3.4.2 Shelf-life of the locally available formulation

### 3.4.3 Storage conditions

### 3.4.4 Bioavailability

### 3.4.5 Specific properties and composition

## 4. USES

### 4.1 Indications

### 4.2 Therapeutic dosage

#### 4.2.1 Adults

#### 4.2.2 Children

### 4.3 Contraindications

## 5. ROUTES OF ENTRY

### 5.1 Oral

### 5.2 Inhalation

### 5.3 Dermal

### 5.4 Eye

### 5.5 Parenteral

### 5.6 Other

## 6. KINETICS

### 6.1 Absorption by route of exposure

### 6.2 Distribution by route of exposure

### 6.3 Biological half-life by route of exposure

### 6.4 Metabolism

### 6.5 Elimination by route of exposure

## 7. PHARMACOLOGY AND TOXICOLOGY

### 7.1 Mode of action

#### 7.1.1 Toxicodynamics

#### 7.1.2 Pharmacodynamics

## 7.2 Toxicity

### 7.2.1 Human data

#### 7.2.1.1 Adults

#### 7.2.1.2 Children

### 7.2.2 Relevant animal data

### 7.2.3 Relevant in vitro data

## 7.3 Carcinogenicity

## 7.4 Teratogenicity

## 7.5 Mutagenicity

## 7.6 Interactions

## 7.7 Main adverse effects

# 8. TOXICOLOGICAL ANALYSES AND BIOMEDICAL INVESTIGATIONS

## 8.1 Material sampling plan

### 8.1.1 Sampling and specimen collection

#### 8.1.1.1 Toxicological analyses

#### 8.1.1.2 Biomedical analyses

#### 8.1.1.3 Arterial blood gas analysis

#### 8.1.1.4 Haematological analyses

#### 8.1.1.5 Other (unspecified) analyses

### 8.1.2 Storage of laboratory samples and specimens

#### 8.1.2.1 Toxicological analyses

#### 8.1.2.2 Biomedical analyses

#### 8.1.2.3 Arterial blood gas analysis

#### 8.1.2.4 Haematological analyses

#### 8.1.2.5 Other (unspecified) analyses

### 8.1.3 Transport of laboratory samples and specimens

#### 8.1.3.1 Toxicological analyses

#### 8.1.3.2 Biomedical analyses

#### 8.1.3.3 Arterial blood gas analysis

#### 8.1.3.4 Haematological analyses

8.1.3.5 Other (unspecified) analyses8.2 Toxicological Analyses and Their Interpretation8.2.1 Tests on toxic ingredient(s) of material8.2.1.1 Simple Qualitative Test(s)8.2.1.2 Advanced Qualitative Confirmation Test(s)8.2.1.3 Simple Quantitative Method(s)8.2.1.4 Advanced Quantitative Method(s)8.2.2 Tests for biological specimens8.2.2.1 Simple Qualitative Test(s)8.2.2.2 Advanced Qualitative Confirmation Test(s)8.2.2.3 Simple Quantitative Method(s)8.2.2.4 Advanced Quantitative Method(s)8.2.2.5 Other Dedicated Method(s)8.2.3 Interpretation of toxicological analyses8.3 Biomedical investigations and their interpretation8.3.1 Biochemical analysis8.3.1.1 Blood, **plasma** or serum8.3.1.2 Urine8.3.1.3 Other fluids8.3.2 Arterial blood gas analyses8.3.3 Haematological analyses8.3.4 Interpretation of biomedical investigations8.4 Other biomedical (diagnostic) investigations and their interpretation8.5 Overall Interpretation of all toxicological analyses and toxicological investigations8.6 References9. CLINICAL EFFECTS9.1 Acute poisoning9.1.1 Ingestion9.1.2 Inhalation9.1.3 Skin exposure

9.1.4 Eye contact9.1.5 Parenteral exposure9.1.6 Other9.2 Chronic poisoning9.2.1 Ingestion9.2.2 Inhalation9.2.3 Skin exposure9.2.4 Eye contact9.2.5 Parenteral exposure9.2.6 Other9.3 Course, prognosis, cause of death9.4 Systematic description of clinical effects9.4.1 Cardiovascular9.4.2 Respiratory9.4.3 Neurological9.4.3.1 CNS9.4.3.2 Peripheral nervous system9.4.3.3 Autonomic nervous system9.4.3.4 Skeletal and smooth muscle9.4.4 Gastrointestinal9.4.5 Hepatic9.4.6 Urinary9.4.6.1 Renal9.4.6.2 Other9.4.7 Endocrine and reproductive systems9.4.8 Dermatological9.4.9 Eye, ear, nose, throat: local effects9.4.10 Haematological9.4.11 Immunological9.4.12 Metabolic

9.4.12.1 Acid-base disturbances9.4.12.2 Fluid and electrolyte disturbances9.4.12.3 Others9.4.13 Allergic reactions9.4.14 Other clinical effects9.4.15 Special risks9.5 Other9.6 Summary10. MANAGEMENT10.1 General principles10.2 Relevant laboratory analyses10.2.1 Sample collection10.2.2 Biomedical analysis10.2.3 Toxicological analysis10.2.4 Other investigations10.3 Life supportive procedures and symptomatic/specific treatment10.4 Decontamination10.5 Elimination10.6 Antidote treatment10.6.1 Adults10.6.2 Children10.7 Management discussion11. ILLUSTRATIVE CASES11.1 Case reports from literature11.2 Internally extracted data on cases11.3 Internal cases12. Additional information12.1 Availability of antidotes12.2 Specific preventive measures12.3 Other



13. REFERENCES14. AUTHOR(S), REVIEWER(S), DATE(S) (INCLUDING UPDATES),  
COMPLETE ADDRESS(ES)

## PHARMACEUTICALS

## 1. NAME

## 1.1 Substance

**Timolol**

## 1.2 Group

beta-blocker; adrenergic beta-receptor blocking agent,  
Class II antiarrhythmic drug

## 1.3 Synonyms

**Timolol** maleate

MK-950

(-)-3-morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole

## 1.4 Identification numbers

## 1.4.1 CAS number

26839-75-8

## 1.4.2 Other numbers

**Timolol** maleate : 26921-17-5

## 1.5 Brand names, Trade names

Betim (Denmark; Netherlands; Leo, Norway; Lovens, Sweden; Leo, UK; Belgium); Blocadren (Frosst, Australia; Belgium; Frosst, Canada; Merck Sharp & Dohme, Italy; Netherlands; Merck Sharp & Dohme, Norway; Merck Sharp & Dohme, South Africa; Spain ; MSD, Sweden; MSD Switzerland; MSD, UK; MSD, USA); Blocanol (Finland); Chibro-Timoptol (Germany); Cusimolol (Cusi, Spain); Oftan-**Timolol** (NAF, Norway); Proflax (Merck Sharp & Dohme, Argentina); Temserin (Frosst, Germany; Greece); Tenopt (Sigma, Australia); Tiloptic (Israel); Timacor (Denmark; Merck Sharp & Dohme-Chibret, France); Timolide (USA); **Timolol** (UK); Timoptic (Merck Sharp & Dohme, Canada; Chibret, Switzerland; Merck Sharp & Dohme, USA; Austria); Timoptol (Frosst, Australia; Merck Sharp & Dohme-Chibret, France; Chibret, Germany; Merck Sharp & Dohme, Italy; Netherlands; New Zealand; South Africa; Merck Sharp & Dohme, UK, Belgium).

## 1.6 Manufacturers, Importers

## 2. SUMMARY

## 2.1 Main risks and target organs

Beta-blocking agents exert their effects by competing with endogenous and/or exogenous beta-adrenergic agonists. **Timolol** is a non-cardioselective beta-blocker (it has similar affinity for beta<sub>1</sub> and beta<sub>2</sub> receptors) and it has no intrinsic sympathomimetic or membrane stabilising effect. The main risks might be an impairment of atrioventricular conduction and a negative inotropic effect (Critchley and Ungar, 1989; Frishman, 1981)

## 2.2 Summary of clinical effects

Only one case of acute poisoning after ingestion of 300 mg **timolol** in a 24 year-old man has been reported. The patient showed moderate toxic symptoms: drowsiness, vertigo, headache, and first degree atrioventricular block which was treated with atropine 1 mg and isoproterenol 5 mg. The patient recovered without sequelae (Tisserand, 1982).

Adverse systemic effects have been reported in patients treated with **timolol** eye drops.

## 2.3 Diagnosis

Symptoms are those anticipated from beta-blockade and include heart block, drowsiness, headache and vertigo. There is,

however, little reported experience of overdose with **timolol**.

**Timolol** may be measured in **plasma** but **plasma** concentrations are not known to be useful for the clinical management of the patient.

#### 2.4 First aid measures and management principles

Patients with poisoning by ingestion of **timolol** should be monitored closely, preferably in an intensive care unit.

Monitor vital signs: ECG, blood pressure, respiration.

Treatment may include:

emesis, gastric lavage, oral activated charcoal


atropine for symptomatic bradycardia, isoproterenol and/or glucagon for atrioventricular block or hypotension

### 3. PHYSICO-CHEMICAL PROPERTIES

#### 3.1 Origin of the substance

Synthetic

#### 3.2 Chemical structure



Molecular weight: 316.42

#### 3.3 Physical properties

##### 3.3.1 Properties of the substance

White, odourless powder.

Melting point: 201.5-202.5 °C.

Soluble 1 in 15 of water, 1 in 21 of alcohol, and 1 in 40 of chloroform; soluble in methanol; practically insoluble in ether.

A 2% solution in water has a pH of 3.8 to 4.3.

Ophthalmic preparations have a pH of 6.5 to 7.5.

(Reynolds, 1989; Merck Index, 1983)

##### 3.3.2 Properties of the locally available formulation

See section 3.3.1.

#### 3.4 Other characteristics

##### 3.4.1 Shelf-life of the substance

No data available.

##### 3.4.2 Shelf-life of the locally available formulation

No data available.

##### 3.4.3 Storage conditions

Store in well-closed containers. Ophthalmic solutions should be protected from light.

##### 3.4.4 Bioavailability

No data available.

##### 3.4.5 Specific properties and composition

No data available.

### 4. USES

#### 4.1 Indications

Oral administration

**Timolol** has been used in the treatment of hypertension, angina pectoris, cardiac arrhythmias, migraine and for the reduction of mortality following myocardial infarction.

Ocular administration

Ophthalmic solutions of **timolol** are used in the treatment of glaucoma to reduce intraocular pressure.

#### 4.2 Therapeutic dosage

##### 4.2.1 Adults

Ophthalmic solutions: The dose for glaucoma is 1 drop of 0.25% solution in each eye twice daily. Dosage may be

increased to 1 drop of 0.5% solution twice daily.

Oral doses in hypertension are 15 to 60 mg daily.

No dose adjustment is required in renal failure or in patients undergoing dialysis.

#### 4.2.2 Children

**Timolol** is not recommended in children. The paediatric dose is unknown.

#### 4.3 Contraindications

**Timolol** is contraindicated in patients with asthma, 2nd and 3rd degree AV block, and cardiogenic shock.

**Timolol** should be used cautiously in patients with chronic obstructive pulmonary diseases, sinus bradycardia, cardiac failure, myasthenia gravis, Raynaud's syndrome.

**Timolol** should not be administered with other beta-blockers.

#### 5. ROUTES OF ENTRY

##### 5.1 Oral

Poisoning after ingestion of **timolol** tablets may occur but only one case has been actually reported.

##### 5.2 Inhalation

No data available.

##### 5.3 Dermal

No case reported.

##### 5.4 Eye

Systemic toxic symptoms may occur after treatment with **timolol** eye drops.

##### 5.5 Parenteral

No data available.

##### 5.6 Other

No data available.

#### 6. KINETICS

##### 6.1 Absorption by route of exposure

Oral

**Timolol** is almost completely (90%) absorbed from the gastrointestinal tract. The **peak plasma concentration** occurs 0.5-3 hours after ingestion (Fourtillan et al, 1981). **Timolol** is subject to a moderate first pass effect (Tocco et al, 1975).

Ocular

The onset of the ocular hypotensive action occurs after 10-20 minutes and lasts for at least 24 hours. (Zimmerman & Kaufman,

1977b). **Timolol** is absorbed systemically; serum concentrations are 2-5 g/l (Affrime et al, 1980; Alvan et al, 1980).

##### 6.2 Distribution by route of exposure

Oral

Bioavailability is about 60 % (Wilson et al, 1982).

Apparent volume of distribution is 1.3 - 1.7 L/kg (Vermeij et al, 1978; Wilson et al, 1982)

**Plasma** protein binding is approximately 10%.

**Timolol** crosses the placenta

Ocular

**Timolol** is distributed in conjunctiva, cornea, sclera, iris, aqueous humor, liver, kidney and lung.

#### Transdermal

After cutaneous application of **timolol** ointment, 50 to 60 % is absorbed systemically (Vlasses et al, 1985)

#### 6.3 Biological half-life by route of exposure

##### Oral

After oral administration, the half-life is 2.5 - 5 hours (Tocco et al, 1975; Vermeij et al, 1978; Else et al, 1978; Ishizaki and Tawara, 1978). The half-life varies according to genetic differences in hepatic metabolism: half-lives of 3.7 and 7.5 hours were reported in extensive and poor metabolisers, respectively (McGourty et al, 1985). The total body clearance is 463 ml/kg/hr (Wilson et al, 1982).

#### 6.4 Metabolism

##### Oral

**Timolol** is extensively metabolized in the liver by hydrolytic cleavage of the morpholino ring with subsequent oxidation. Following an oral dose, 80 % is metabolized and 20% is eliminated unchanged in urine (Tocco et al, 1975). Metabolism is dependent on genetic polymorphism.

#### 6.5 Elimination by route of exposure

Oral: Kidney

About 20% of the dose is eliminated unchanged in the urine and 40 to 60% as metabolites (Tocco et al, 1975).

#### Breast milk

**Timolol** is present in breast milk but the total amount of **timolol** ingested by an infant who is breast feeding is unlikely to cause any clinical effects. Following a maternal oral dose, the milk/**plasma** ratio is 0.80.

Ocular: Breast milk

Following ocular instillation, the **concentration** in breast milk was approximately 6 times higher (5.6 ng/ml) than in serum (0.93 ng/ml) (Lustgarten and Podos, 1983). However, the total amount of **timolol** ingested by an infant who is breast feeding is unlikely to cause any clinical effects.

### 7. PHARMACOLOGY AND TOXICOLOGY

#### 7.1 Mode of action

##### 7.1.1 Toxicodynamics

At toxic doses, **timolol** may exert a pronounced negative chronotropic and negative inotropic cardiac effect.

##### 7.1.2 Pharmacodynamics

The exact mechanism whereby **timolol** reduces ocular pressure is still not known. The most likely action is by decreasing the secretion of aqueous humor (Zimmerman et al, 1977)

At therapeutic doses, **timolol** slightly decreases heart rate, supraventricular conduction and cardiac output.

#### 7.2 Toxicity

##### 7.2.1 Human data

##### 7.2.1.1 Adults

Only one case of acute poisoning with **timolol** (after ingestion of 300 mg) has been reported;

this patient showed moderately severe symptoms (Tisserand, 1982).

#### 7.2.1.2 Children

An 18 month-old girl developed bradycardia, respiratory depression and cyanosis 30 minutes after the administration of **timolol** eye drops (Williams and Ginther, 1982).

#### 7.2.2 Relevant animal data

The oral LD50 is 1190 mg/kg in mice and 900 mg/kg in rats (RTECS, 1980).

#### 7.2.3 Relevant in vitro data

No data available.

#### 7.3 Carcinogenicity

No data available.

#### 7.4 Teratogenicity

No epidemiological studies of congenital abnormalities among infants born to women treated with **timolol** during pregnancy have been reported.

#### 7.5 Mutagenicity

No data available.

#### 7.6 Interactions

Sinus bradycardia has been reported after concomitant treatment with **timolol** eye drops and quinidine.

#### 7.7 Main adverse effects

### 8. TOXICOLOGICAL ANALYSES AND BIOMEDICAL INVESTIGATIONS

#### 8.1 Material sampling plan

##### 8.1.1 Sampling and specimen collection

###### 8.1.1.1 Toxicological analyses

###### 8.1.1.2 Biomedical analyses

###### 8.1.1.3 Arterial blood gas analysis

###### 8.1.1.4 Haematological analyses

###### 8.1.1.5 Other (unspecified) analyses

##### 8.1.2 Storage of laboratory samples and specimens

###### 8.1.2.1 Toxicological analyses

###### 8.1.2.2 Biomedical analyses

###### 8.1.2.3 Arterial blood gas analysis

###### 8.1.2.4 Haematological analyses

###### 8.1.2.5 Other (unspecified) analyses

##### 8.1.3 Transport of laboratory samples and specimens

###### 8.1.3.1 Toxicological analyses

###### 8.1.3.2 Biomedical analyses

###### 8.1.3.3 Arterial blood gas analysis

###### 8.1.3.4 Haematological analyses

###### 8.1.3.5 Other (unspecified) analyses

#### 8.2 Toxicological Analyses and Their Interpretation

##### 8.2.1 Tests on toxic ingredient(s) of material

###### 8.2.1.1 Simple Qualitative Test(s)

###### 8.2.1.2 Advanced Qualitative Confirmation Test(s)

###### 8.2.1.3 Simple Quantitative Method(s)

###### 8.2.1.4 Advanced Quantitative Method(s)

##### 8.2.2 Tests for biological specimens

###### 8.2.2.1 Simple Qualitative Test(s)

###### 8.2.2.2 Advanced Qualitative Confirmation Test(s)

###### 8.2.2.3 Simple Quantitative Method(s)

###### 8.2.2.4 Advanced Quantitative Method(s)

###### 8.2.2.5 Other Dedicated Method(s)

##### 8.2.3 Interpretation of toxicological analyses

#### 8.3 Biomedical investigations and their interpretation

##### 8.3.1 Biochemical analysis

###### 8.3.1.1 Blood, **plasma** or serum

Routine biochemical investigations (i.e. sodium, potassium, creatinine and/or urea, glucose).

###### 8.3.1.2 Urine

- 8.3.1.3 Other fluids
- 8.3.2 Arterial blood gas analyses
  - Should be obtained on admission.
- 8.3.3 Haematological analyses
- 8.3.4 Interpretation of biomedical investigations
  - Following a single oral dose of 20 mg, the mean **peak plasma concentration** is 83 microgram/l (range: 50 - 103) (Fourtillan et al, 1981). The **plasma concentration** required for beta-blocking activity is estimated to be 5 - 10 microgram/l.
- 8.4 Other biomedical (diagnostic) investigations and their interpretation
- 8.5 Overall Interpretation of all toxicological analyses and toxicological investigations
- 8.6 References
- 9. CLINICAL EFFECTS
  - 9.1 Acute poisoning
    - 9.1.1 Ingestion
      - Only one case of acute poisoning of **timolol** following ingestion of 300 mg in a 24 year-old man has been reported. The patient showed moderately severe symptoms, including drowsiness, vertigo, headache, first-degree atrioventricular block (Tisserand, 1982).
    - 9.1.2 Inhalation
      - No data available.
    - 9.1.3 Skin exposure
      - No data available.
    - 9.1.4 Eye contact
      - Adverse systemic effects have been reported after treatment with ophtalmic solutions of **timolol**. See section 7.7.
    - 9.1.5 Parenteral exposure
      - No data available.
    - 9.1.6 Other
      - No data available.
  - 9.2 Chronic poisoning
    - 9.2.1 Ingestion
      - No data available.
    - 9.2.2 Inhalation
      - No data available.
    - 9.2.3 Skin exposure
      - No data available.
    - 9.2.4 Eye contact
      - Dryness of the eye has been reported in a man treated by **timolol** 75 mg daily (Fraiss and Batley, 1979)
        - Corneal anaesthesia was observed in a patient treated with **timolol** eye drops (Calissendorff, 1981).
    - 9.2.5 Parenteral exposure
      - No data available.
    - 9.2.6 Other
      - No data available.
  - 9.3 Course, prognosis, cause of death
    - Only one case of acute poisoning following ingestion of 300 mg **timolol** in a 24 year-old man has been reported. The patient showed moderately severe symptoms: drowsiness, vertigo, headache, first degree atrioventricular block which was treated by atropine 1 mg and isoproterenol 5 mg. The patient recovered without sequelae (Tisserand, 1982). No deaths have been reported.
  - 9.4 Systematic description of clinical effects
    - 9.4.1 Cardiovascular
      - Acute

First-degree atrioventricular block has been reported after ingestion of 300 mg; blood pressure was 120/80 mmHg and the heart rate was 58/min (Tisserand, 1982).

Bradycardia, hypotension, atrioventricular block and congestive cardiac failure may occur after administration of **timolol**.

Chronic: No data available.

#### 9.4.2 Respiratory

Acute

Reversible respiratory arrest was observed in a 62-year-old woman after instillation of **timolol** eye drops (Botet et al, 1986) and may occur after oral administration.

Bronchospasm may occur in susceptible patients after administration of **timolol**.

Chronic: No data available.

#### 9.4.3 Neurological

##### 9.4.3.1 CNS

Acute

Drowsiness, vertigo, headache have been reported in one case after ingestion of 300 mg (Tisserand, 1982).

Fatigue, confusion, depression, hallucinations have been reported after administration of **timolol**.

Chronic: No data available.

##### 9.4.3.2 Peripheral nervous system

Acute

Worsening of myasthenia gravis may occur after administration of **timolol**.

Chronic: No data available.

##### 9.4.3.3 Autonomic nervous system

Acute: Effects of beta-blockade.

Chronic: Effects of beta-blockade.

##### 9.4.3.4 Skeletal and smooth muscle

No data available.

#### 9.4.4 Gastrointestinal

Acute

Abdominal pain, nausea, vomiting and diarrhoea may occur after administration of **timolol** orally or as eye drops.

Chronic: No data available.

#### 9.4.5 Hepatic

No data available.

#### 9.4.6 Urinary

##### 9.4.6.1 Renal

No data available.

##### 9.4.6.2 Other

No data available.

## 9.4.7 Endocrine and reproductive systems

No data available.

## 9.4.8 Dermatological

Acute: Urticaria may be observed.

Chronic: No data available.

## 9.4.9 Eye, ear, nose, throat: local effects

Acute

Eyelid erythema and oedema has been reported following ocular administration.

Chronic: No data available.

## 9.4.10 Haematological

No data available.

## 9.4.11 Immunological

No data available.

## 9.4.12 Metabolic

## 9.4.12.1 Acid-base disturbances

No data available.

## 9.4.12.2 Fluid and electrolyte disturbances

Hyperkalaemia has been reported.

## 9.4.12.3 Others

No data available.

## 9.4.13 Allergic reactions

No data available.

## 9.4.14 Other clinical effects

Sexual dysfunction following usual doses of topical ocular **timolol** has been reported and may also occur after oral administration.

## 9.4.15 Special risks

**Timolol** is eliminated in breast milk but the total amount of **timolol** ingested by an infant who is breast feeding is unlikely to cause clinical effects.

No epidemiological studies of congenital anomalies among infants born to women treated with **timolol** during pregnancy have been reported.

## 9.5 Other

No data available.

## 9.6 Summary

## 10. MANAGEMENT

## 10.1 General principles

Patients with poisoning by ingestion of **timolol** should be monitored preferably in an intensive care unit.

Monitor vital signs: ECG, blood pressure, respiration.

Treatment may include:

emesis, gastric lavage, oral activated charcoal

atropine for symptomatic bradycardia, isoproterenol and/or glucagon for atrioventricular block or hypotension

## 10.2 Relevant laboratory analyses

## 10.2.1 Sample collection

## 10.2.2 Biomedical analysis

## 10.2.3 Toxicological analysis

Measurement of **plasma timolol** concentrations is not useful for the clinical management.

## 10.2.4 Other investigations

## 10.3 Life supportive procedures and symptomatic/specific treatment



See also monograph on PROPRANOLOL.

#### Cardiovascular disturbances:

Sinus bradycardia may be treated with intravenous atropine.

Isoproterenol is the drug of choice for the treatment of atrioventricular block. Hypotension may require administration of isoproterenol or glucagon.

#### Respiratory:

Bronchospasm may be treated with beta-2-agonists or aminophylline.

#### 10.4 Decontamination

Although emesis, gastric lavage and oral activated charcoal have not been evaluated in **timolol** poisoning but they may be indicated in poisoning by ingestion.

#### 10.5 Elimination

The efficacy of forced diuresis has not been evaluated.

The elimination of **timolol** is not significantly enhanced by haemodialysis or peritoneal dialysis and these procedures cannot be recommended.

#### 10.6 Antidote treatment

##### 10.6.1 Adults

##### 10.6.2 Children

#### 10.7 Management discussion

### 11. ILLUSTRATIVE CASES

#### 11.1 Case reports from literature

Tisserand (1982) reported a case of acute poisoning after ingestion of 300 mg of **timolol** in a 24 year-old man. The patient developed moderately severe symptoms, including drowsiness, vertigo, headache, first degree atrioventricular block. Treatment included atropine 1 mg and isoproterenol 5 mg. The patient recovered without any complications.

#### 11.2 Internally extracted data on cases

#### 11.3 Internal cases

### 12. Additional information

#### 12.1 Availability of antidotes

No data available.

#### 12.2 Specific preventive measures

No data available.

#### 12.3 Other

No data available.

### 13. REFERENCES

Affrime MB et al (1980). Dynamics and kinetics of ophthalmic **timolol**.

Clin Pharmacol Ther 27: 471

Alvan G (1980). Absorption of ocular **timolol**. Clin Pharmacokinetics 5: 95.

Botet C, Grau J, Benito P et al (1986). **Timolol** ophthalmic solution and respiratory arrest. Ann Intern Med 105: 306.

Calissendorff B (1981). Corneal anesthesia after treatment with maleate, a case report. Acta Ophthalmologica 59: 347.

Cheymol G, Biour M (1985). Données récentes sur les effets

indésirables des inhibiteurs bêta-adrénergiques. Thérapie 40: 423-8.

Critchley JAJH, Ungar A (1989). The management of acute poisoning due to beta-adrenoceptor antagonists. Med Toxicol 4: 32-45.

Drugdex, Micromedex Inc., 1991.

Dukes MNG (1984). Side Effects of Drugs, Annual 8. Elsevier, Amsterdam.

Else et al (1978). Eur J Clin Pharmacol 14: 431.

Fourtillan JB, Courtois P, Lefebvre MA et al (1981). Pharmacokinetics of oral **timolol** studied by mass fragmentography Eur J Clin Pharmacol 19: 193-196.

Frais MA, Baley TJ (1979). Ocular reaction to **timolol** maleate. Postgrad Med J 55: 884.

Fraunfelder FT, Meyer SM (1987). Systemic reactions to ophthalmic drug preparations. Med Toxicol 2: 287-293.

Frishman WH (1982). Atenolol and **timolol**, two new systemic beta-adrenoceptor antagonists. New Eng J Med 306: 1456-1462.

Ishizaki T, Tawara K (1978). Eur J Clin Pharmacol 14: 7

Lustgarten JS, Podos SM (1983). Topical **timolol** and the nursing mother. Arch Ophthalmol 101: 1381-1382.

Lustgarten JS (1988). Topical timol-induced arthropathy. Am J Ophthalmol 105: 687-688.

Reynolds JEF (1989). Martindale, The Extra Pharmacopoeia. The Pharmaceutical Press. London.

McGourty JC, Silas JH, Fleming JJ et al (1985). Pharmacokinetics and beta-blocking effects of **timolol** in poor and extensive metabolizers of debrisoquine. Clin Pharmacol Ther 38: 409-413.

Merck Index (1983). An encyclopedia of chemicals, drugs and biologicals, 10th ed, Merck Inc.

RTECS, (1980). Registry of Toxic Effects of Chemical Substances. Lewis RL (ed).

Tisserand D (1982). Intoxications volontaires aiguës par les beta-bloquants. A propos de 19 cas. Thèse Méd., Nancy I.

Tocco DJ et al (1975). Physiological disposition of and metabolism of **timolol** in man and laboratory animals. Drug Metab Dispos 3: 361.

Vermeij P et al (1978). The disposition of **timolol** in man. J Pharm Pharmacol 30: 53.

Vlasses PH, Ribeiro LGT, Rotmensch HH et al (1985). Initial evaluation of transdermal **timolol**: serum concentrations and beta-blockade. J Cardiovascular Pharmacol 7: 245-250.

Williams T, Ginther WH. Hazard of ophthalmic **timolol**. New Eng J

Med 306: 1485-1486.

Wilson TW, Firor WB, Johnson GL et al (1982). **Timolol** and propranolol: bioavailability, **plasma** concentrations and beta-blockade. Clin Pharmacol Ther 32: 676-685.

Zimmerman T, Kaufman H (1977a). **Timolol**: a beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 95: 601.

Zimmerman T, Kaufman H (1977b). **Timolol**: dose response and duration of action. Arch Ophthalmol 95: 605.

14. AUTHOR(S), REVIEWER(S), DATE(S) (INCLUDING UPDATES), COMPLETE ADDRESS(ES)

Authors: Jaeger A., Flesch F. Kopferschmitt J., Sauder Ph.  
Service de Réanimation Médicale et Centre Anti-Poisons

CHU, Pavillon Pasteur  
1 Place de l'Hôpital  
67091 Strasbourg Cédex  
France

Tel: 33-88161144  
Fax: 33-88161330

Date: 28 March 1991

Peer Review: Adelaide, Australia, April 1991

See Also:

Toxicological Abbreviations

This is Google's cache of [http://www.drugs.com/pdr/TIMOLOL\\_HEMIHYDRATE.html](http://www.drugs.com/pdr/TIMOLOL_HEMIHYDRATE.html) as retrieved on May 13, 2006 07:27:25 GMT.

Google's cache is the snapshot that we took of the page as we crawled the web.

The page may have changed since that time. [Click here](#) for the current page without highlighting.

This cached page may reference images which are no longer available. [Click here](#) for the cached text only.

To link to or bookmark this page, use the following url: [http://www.google.com/search?](http://www.google.com/search?q=cache:RLiz9ohwZmMJ:www.drugs.com/pdr/TIMOLOL_HEMIHYDRATE.html+half+life+timolol+pdr&hl=en&gl=us&ct=clnk&cd=1)

[q=cache:RLiz9ohwZmMJ:www.drugs.com/pdr/TIMOLOL\\_HEMIHYDRATE.html+half+life+timolol+pdr&hl=en&gl=us&ct=clnk&cd=1](http://www.google.com/search?q=cache:RLiz9ohwZmMJ:www.drugs.com/pdr/TIMOLOL_HEMIHYDRATE.html+half+life+timolol+pdr&hl=en&gl=us&ct=clnk&cd=1)

Google is neither affiliated with the authors of this page nor responsible for its content.

These search terms have been highlighted: **half life timolol pdr**

**All Quotes Insurance**  
Instant Quotes from Multiple Agents!

### Get the Health Coverage You Need TODAY!

Individual, Family, Vision, Dental, Chiropractic, Prescription

Now Featuring **ClickCall** TECHNOLOGY!

Get Multiple Quotes Now

Get Rates

Individual Health

Family Health

Discount Health

**Drugs.com**  
Drug Information Online

Prescription Drug Information for Consumers & Professionals

[Home](#) | [New Drugs](#) | [Latest News](#) | [Drug Interactions](#) | [Pill Identification](#) | [Images](#) | [Forum](#)

Drugs.com - prescription drug and medicine information available on over 24,000 approved medications and pharmaceuticals, including side effects and drug interactions.

[Log-out](#) | [Edit Profile](#)

#### Advertisement

#### Lower Blood Pressure, No Side Effects

Clinically proven medical device to lower blood pressure without side effects.  
[www.resperate.com](http://www.resperate.com)

#### Kill Your Appetite with All Natural Hoodia!

Hoodia has been featured on 60 Minutes as a natural way to suppress appetite. Learn about Hoodia.  
[www.hoodia-advice.org](http://www.hoodia-advice.org)

#### Endless Pools, Free DVD

Swimming Year-round, Indoors or Out, Private & Convenient, Install in New or Existing Spaces!  
[www.EndlessPools.com](http://www.EndlessPools.com)

[Buy a Link Now](#)

**Special Offers**  
[Free GERD Information Kit and Trial Offer](#)

[Breast Cancer Awareness](#)

[Better Management and](#)

#### SEARCH >>

Advanced Search

DRUG SEARCH

INTERNET SEARCH

Or click the first letter of a drug name: **A B C D E F G H I J K L M N O P Q R S T U V W X Y Z**

#### Hottest Diet in USA

Lose 20 lbs in 3 weeks! As seen on Oprah & 60 Minutes.  
[www.WulongforLife.com](http://www.WulongforLife.com)

#### Us

Us Shop Target.com  
[www.Target.com](http://www.Target.com)

#### Cell Phone Ring Tones

Download The Hottest Music Can You Say Free Ringtones?  
[blinko.com](http://blinko.com)

#### Popular Searches

[Lipitor](#)

[Viagra](#)

[Cialis](#)

[Levitra](#)

[Zoloft](#)

[Hair Transplant](#)

[Health Insurance](#)

[Healthy Diet](#)

[Lose Weight](#)

[Pain Relief](#)

#### Advertisement

Ads by Google

PRINTABLE VERSION

ADD TO FAVORITES

EMAIL THIS PAGE TO A FRIEND

### PDR Drug information for

### TIMOLOL HEMIHYDRATE

Manufacturer: Vistakon

### DESCRIPTION

Treatment of Acid Reflux DiseaseShorter Hospital Stays with MIPWhat is BPH? Do I have it?**For Professionals****In Partnership With**

- [GI Consult](#)
- [Diagnosis at a Glance](#)
- [Tricks of the Trade](#)
- [Would you miss this diagnosis?](#)
- [Interactive Learning Cases](#)

**From our sponsors****Breast Cancer Awareness**

**Learn about a treatment for nail fungus infection**

**Categories**[Allergies & Hayfever](#)[Diabetes](#)[Gastro Center](#)[Weight Loss](#)[AIDS/HIV](#)[Cancer & Oncology](#)[Mental Health & Depression](#)[Cholesterol](#)[Hair Loss](#)[Muscular Injuries & Arthritis](#)[Pain Relief](#)[Sexual Health](#)


Betimol® (timolol ophthalmic solution), 0.25% and 0.5%, is a non-selective beta-adrenergic antagonist for ophthalmic use. The chemical name of the active ingredient is (S)-1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-2-propanol. Timolol hemihydrate is the levo isomer. Specific rotation is  $[(\alpha)]^{25}_{405\text{nm}} = -16^\circ$  (C=10% as the hemihydrate form in 1N HCl).

## ► Having Surgery?

## Having Surgery?



The molecular formula of timolol is Formula C<sub>13</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub>S and its structural formula is:



Timolol (as the hemihydrate) is a white, odorless, crystalline powder which is slightly soluble in water and freely soluble in ethanol. Timolol hemihydrate is stable at room temperature.

Betimol® is a clear, colorless, isotonic, sterile, microbiologically preserved phosphate buffered aqueous solution.

It is supplied in two dosage strengths, 0.25% and 0.5%.

Each mL of Betimol® 0.25% contains 2.56 mg of timolol hemihydrate equivalent to 2.5 mg timolol.

Each mL of Betimol® 05% contains 5.12 mg of timolol hemihydrate equivalent to 5.0 mg timolol.

Inactive ingredients: monosodium and disodium phosphate dihydrate to adjust pH (6.5 - 7.5) and water for injection, benzalkonium chloride 0.01% added as preservative.

The osmolality of Betimol® is 260 to 320 mOsm/kg.

## CLINICAL PHARMACOLOGY

Timolol is a non-selective beta-adrenergic antagonist.

It blocks both beta<sub>1</sub> - and beta<sub>2</sub> -adrenergic receptors. Timolol does not have significant intrinsic sympathomimetic activity, local anesthetic (membrane-stabilizing) or direct myocardial depressant activity.

**Timolol**, when applied topically in the eye, reduces normal and elevated intraocular pressure (IOP) whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss. The higher the level of IOP, the greater the likelihood of glaucomatous visual field loss and optic nerve damage. The predominant mechanism of ocular hypotensive action of topical beta-adrenergic blocking agents is likely due to a reduction in aqueous humor production.

In general, beta-adrenergic blocking agents reduce cardiac output both in healthy subjects and patients with heart diseases. In patients with severe impairment of myocardial function, beta-adrenergic receptor blocking agents may inhibit sympathetic stimulatory effect necessary to maintain adequate cardiac function. In the bronchi and bronchioles, beta-adrenergic receptor blockade may also increase airway resistance because of unopposed parasympathetic activity.

## Pharmacokinetics

When given orally, **timolol** is well absorbed and undergoes considerable first pass metabolism. **Timolol** and its metabolites are primarily excreted in the urine. The half-life of **timolol** in plasma is approximately 4 hours.

## Clinical Studies

In two controlled multicenter studies in the U.S., Betimol® 0.25% and 0.5% were compared with respective **timolol** maleate eyedrops. In these studies, the efficacy and safety profile of Betimol® was similar to that of **timolol** maleate.

## INDICATIONS AND USAGE

Betimol® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

## CONTRAINDICATIONS

Betimol® is contraindicated in patients with overt heart failure, cardiogenic shock, sinus bradycardia, second- or third-degree atrioventricular block, bronchial asthma or history of bronchial asthma, or severe chronic obstructive pulmonary disease, or hypersensitivity to any component of this product.

## WARNINGS

As with other topically applied ophthalmic drugs, Betimol® is absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely, death in association with cardiac failure have been reported following systemic or topical administration of beta-adrenergic blocking agents.

**Cardiac Failure:** Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe cardiac failure.

In patients without a history of cardiac failure, continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. Betimol® should be discontinued at the first sign or symptom of cardiac failure.

**Obstructive Pulmonary Disease:** Patients with chronic obstructive pulmonary disease (e.g. chronic bronchitis, emphysema) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial asthma or a history of bronchial asthma which are contraindications) should in general not receive beta-blocking agents.

**Major Surgery:** The necessity or desirability of withdrawal of beta-adrenergic

blocking agents prior to a major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures. Some patients receiving beta-adrenergic receptor blocking agents have been subject to protracted severe hypotension during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, gradual withdrawal of beta-adrenergic receptor blocking agents is recommended. If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of beta-adrenergic agonists.

**Diabetes Mellitus:** Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute hypoglycemia.

**Thyrotoxicosis:** Beta-adrenergic blocking agents may mask certain clinical signs (e.g. tachycardia) of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents which might precipitate a thyroid storm.

## PRECAUTIONS

### General

Because of the potential effects of beta-adrenergic blocking agents relative to blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. If signs or symptoms suggesting reduced cerebral blood flow develop following initiation of therapy with Betimol®, alternative therapy should be considered.

There have been reports of bacterial keratitis associated with the use of multiple dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. (See [PRECAUTIONS , Information for Patients](#) .)

**Muscle Weakness:** Beta-adrenergic blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g. diplopia, ptosis, and generalized weakness). Beta-adrenergic blocking agents have been reported rarely to increase muscle weakness in some patients with myasthenia gravis or myasthenic symptoms.

In angle-closure glaucoma, the goal of the treatment is to reopen the angle. This requires constricting the pupil. Betimol® has no effect on the pupil. Therefore, if timolol is used in angle-closure glaucoma, it should always be combined with a miotic and not used alone.

**Anaphylaxis:** While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions.

The preservative benzalkonium chloride may be absorbed by soft contact lenses. Patients who wear soft contact lenses should wait 5 minutes after instilling Betimol® before they insert their lenses.

### Information for Patients

Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures.

Patients should also be instructed that ocular solutions can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and

subsequent loss of vision may result from using contaminated solutions. (See PRECAUTIONS , General .)

Patients requiring concomitant topical ophthalmic medications should be instructed to administer these at least 5 minutes apart.

Patients with bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second- or third-degree atrioventricular block, or cardiac failure should be advised not to take this product (See CONTRAINDICATIONS .)

## Drug Interactions

**Beta-adrenergic blocking agents:** Patients who are receiving a beta-adrenergic blocking agent orally and Betimol® should be observed for a potential additive effect either on the intraocular pressure or on the known systemic effects of beta-blockade.

Patients should not usually receive two topical ophthalmic beta-adrenergic blocking agents concurrently.

**Catecholamine-depleting drugs:** Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.

**Calcium antagonists:** Caution should be used in the co-administration of beta-adrenergic blocking agents and oral or intravenous calcium antagonists, because of possible atrioventricular conduction disturbances, left ventricular failure, and hypotension. In patients with impaired cardiac function, co-administration should be avoided.

**Digitalis and calcium antagonists** The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time.

**Injectable Epinephrine:** (See PRECAUTIONS , General , Anaphylaxis .)

## Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity of timolol (as the maleate) has been studied in mice and rats. In a two-year study orally administered timolol maleate (300mg/kg/day) (approximately 42,000 times the systemic exposure following the maximum recommended human ophthalmic dose) in male rats caused a significant increase in the incidence of adrenal pheochromocytomas; the lower doses, 25 mg or 100 mg/kg daily did not cause any changes.

In a life span study in mice the overall incidence of neoplasms was significantly increased in female mice at 500 mg/kg/day (approximately 71,000 times the systemic exposure following the maximum recommended human ophthalmic dose). Furthermore, significant increases were observed in the incidences of benign and malignant pulmonary tumors, benign uterine polyps, as well as mammary adenocarcinomas. These changes were not seen at the daily dose level of 5 or 50 mg/kg (approximately 700 or 7,000, respectively, times the systemic exposure following the maximum recommended human ophthalmic dose). For comparison, the maximum recommended human oral dose of timolol maleate is 1 mg/kg/day.

Mutagenic potential of timolol was evaluated *in vivo* in the micronucleus test and cytogenetic assay and *in vitro* in the neoplastic cell transformation assay and Ames test. In the bacterial mutagenicity test (Ames test) high concentrations of timolol maleate (5000 and 10,000 g/plate) statistically significantly increased the number of revertants in *Salmonella typhimurium* TA100, but not in the other three strains tested. However, no consistent dose-response was observed nor did the number of revertants reach the double of the control value, which is regarded as one of the criteria for a positive result in the Ames test. *In vivo* genotoxicity tests (the mouse micronucleus test and cytogenetic assay) and *in vitro* the neoplastic cell



transformation assay were negative up to dose levels of 800 mg/kg and 100 g/mL, respectively.

No adverse effects on male and female fertility were reported in rats at **timolol** oral doses of up to 150 mg/kg/day (21,000 times the systemic exposure following the maximum recommended human ophthalmic dose).

### **Pregnancy Teratogenic effects:**

Category C: Teratogenicity of **timolol** (as the maleate) after oral administration was studied in mice and rabbits. No fetal malformations were reported in mice or rabbits at a daily oral dose of 50 mg/kg (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose). Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose in this case without apparent maternotoxicity.

There are no adequate and well-controlled studies in pregnant women. **Betimol®** should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

### **Nursing mothers:**

Because of the potential for serious adverse reactions in nursing infants from **timolol**, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

### **Pediatric use:**

Safety and efficacy in pediatric patients have not been established.

## **ADVERSE REACTIONS**

The most frequently reported ocular event in clinical trials was burning/stinging on instillation and was comparable between **Betimol®** and **timolol** maleate (approximately one in eight patients).

The following adverse events were associated with use of **Betimol®** in frequencies of more than 5% in two controlled, double-masked clinical studies in which 184 patients received 0.25% or 0.5% **Betimol®**:

### **OCULAR:**

Dry eyes, itching, foreign body sensation, discomfort in the eye, eyelid erythema, conjunctival injection, and headache.

### **BODY AS A WHOLE:**

Headache.

The following side effects were reported in frequencies of 1 to 5%:

### **OCULAR:**

Eye pain, epiphora, photophobia, blurred or abnormal vision, corneal fluorescein staining, keratitis, blepharitis and cataract.

**BODY AS A WHOLE:**

Allergic reaction, asthenia, common cold and pain in extremities.

**CARDIOVASCULAR:**

Hypertension.

**DIGESTIVE:**

Nausea.

**METABOLIC/NUTRITIONAL:**

Peripheral edema.

**NERVOUS SYSTEM/PSYCHIATRY:**

Dizziness and dry mouth.

**RESPIRATORY:**

Respiratory infection and sinusitis.

In addition, the following adverse reactions have been reported with ophthalmic use of beta blockers:

**OCULAR:**

Conjunctivitis, blepharoptosis, decreased corneal sensitivity, visual disturbances including refractive changes, diplopia and retinal vascular disorder.

**BODY AS A WHOLE:**

Chest pain.

**CARDIOVASCULAR:**

Arrhythmia, palpitation, bradycardia, hypotension, syncope, heart block, cerebral vascular accident, cerebral ischemia, cardiac failure and cardiac arrest.

**DIGESTIVE:**

Diarrhea.

**ENDOCRINE:**

Masked symptoms of hypoglycemia in insulin dependent diabetics (See WARNINGS ).

**NERVOUS SYSTEM/PSYCHIATRY:**

Depression, impotence, increase in signs and symptoms of myasthenia gravis and paresthesia.

**RESPIRATORY:**

Dyspnea, bronchospasm, respiratory failure and nasal congestion.

**SKIN:**

Alopecia, hypersensitivity including localized and generalized rash, urticaria.

**OVERDOSAGE**

No information is available on overdosage with Betimol®. Symptoms that might be expected with an overdose of a beta-adrenergic receptor blocking agent are bronchospasm, hypotension, bradycardia, and acute cardiac failure.

**DOSAGE AND ADMINISTRATION**

Betimol® Ophthalmic Solution is available in concentrations of 0.25 and 0.5 percent. The usual starting dose is one drop of 0.25 percent Betimol® in the affected eye(s) twice a day. If the clinical response is not adequate, the dosage may be changed to one drop of 0.5 percent solution in the affected eye(s) twice a day.

If the intraocular pressure is maintained at satisfactory levels, the dosage schedule may be changed to one drop once a day in the affected eye(s). Because of diurnal variations in intraocular pressure, satisfactory response to the once-a-day dose is best determined by measuring the intraocular pressure at different times during the day.

Since in some patients the pressure-lowering response to Betimol® may require a few weeks to stabilize, evaluation should include a determination of intraocular pressure after approximately 4 weeks of treatment with Betimol®.

Dosages above one drop of 0.5 percent Betimol® twice a day generally have not been shown to produce further reduction in intraocular pressure. If the patient's intraocular pressure is still not at a satisfactory level on this regimen, concomitant therapy with pilocarpine and other miotics, and/or epinephrine, and/or systemically administered carbonic anhydrase inhibitors, such as acetazolamide can be instituted.

**HOW SUPPLIED**

Betimol® (timolol ophthalmic solution) is a clear, colorless solution.

Betimol® 0.25% is supplied in a white, opaque, plastic, ophthalmic dispenser bottle with a controlled drop tip as follows:

NDC 68669-522-05 5.0mL fill in 5 cc container

NDC 68669-522-10 10mL fill in 11 cc container

NDC 68669-522-15 15mL fill in 15 cc container

Betimol® 0.5% is supplied in a white, opaque, plastic, ophthalmic dispenser bottle with a controlled drop tip as follows:

NDC 68669-525-05 5.0mL fill in 5 cc container

NDC 68669-525-10 10mL fill in 11 cc container

NDC 68669-525-15 15mL fill in 15 cc container

Rx Only

**STORAGE**

Store between 15-30°C (59-86°F). Do not freeze. Protect from light.

**MARKETED BY:**

VISTAKON® Pharmaceuticals, LLC

Jacksonville, FL 32256 USA

**MANUFACTURED BY:**

Santen Oy, P.O. Box 33

FIN-33721 Tampere, Finland

Santen®


March 2004 Version


VISTAKON® Pharmaceuticals, LLC

**PRODUCT PHOTO(S):**

NOTE: These photos can be used only for identification by shape, color, and imprint. They do not depict actual *or relative* size.

The product samples shown here have been supplied by the manufacturer and reproduced in full color by PDR as a quick-reference identification aid. While every effort has been made to assure accurate reproduction, please remember that any visual identification should be considered preliminary. In cases of poisoning or suspected overdose, the drug's identity should be verified by chemical analysis.





The information contained in the Thomson Healthcare (Micromedex) products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Healthcare does not assume any responsibility or risk for your use of the Thomson Healthcare products.

## ADVERTISEMENT

[Home](#) - [Drug Interactions](#) - [Pill Identification](#) - [Question.com](#)

[Advertising](#) - [FAQs](#) - [Links](#) - [Privacy Policy](#) - [Terms of Use](#) - [Contact Us](#) - [Top Drugs](#) - [Merchandise Store](#) - [About Drugs.com](#) - [Editorial Policy](#)

The drugs.com drug database is powered by Micromedex™ and Multum™.

Micromedex data last updated 20 April 2006.

Micromedex Physicians Desk Reference data last updated 3 April 2006.

Multum data last updated 1 May 2006.

© Copyright 2006 Drugs.com



We subscribe to the HONcode principles. [Verify here.](#)